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Introduction :  
  Acinetobacter has emerged as an important nosocomial pathogen, 
known to cause different kinds of opportunistic infections.  
Acinetobacter species are gram negative, strongly aerobic, non fastidious, 
catalase positive, oxidase negative, non motile, encapsulated coccobacilli. 
Acinetobacter baumanni is now recognized to be the species of great 
clinical importance being capable of causing life threatening infections 
including pneumonia, septicemia, wound sepsis, urinary tract infection. 
One of the striking feature of genus Acinetobacter is the ability to develop 
antibiotic resistant extremely rapid in response to challenge with new 
antibiotics. 
Aims and objectives :  
  To know the prevalence of Acinetobacter among various clinical 
samples. To study different species of Acinetobacter. To assess the 
antimicrobial susceptibility pattern of Acinetobacter. To study molecular 
characterization of Acinetobacter.  
Materials and Methods : 
  Clinical samples (urine, blood, pus and sputum) from different 
wards were inoculated on routine media. Acinetobacter was identified by 
gram staining ,hanging drop, oxidase, catalase test and other biochemical 
test. Speciation of Acinetobacter into various genomic species was done 
by using a battery of biochemical test. Disc Diffusion susceptibility test 
was performed on Mueller Hinton agar and Molecular characterization by  
conventional PCR. 
Result : 
   Out of the 4643 culture positive samples, 80 samples were found 
to be Acinetobacter. The prevalence of Acinetobacter was 1.7%.  
Acinetobacter baumannii (77.5%) and Acinetobacter lwoffii (22.5%) 
were the two species isolated. Acinetobacter strains were resistant to 
Ampicillin (81%), Gentamicin (36%), Amikacin (29%,), Cephalexin 
(86%), Ceftriaxone (44%), Ciprofloxacin (49%), Cotrimoxazole (58%), 
Chloramphenicol (66%). 8% of the total isolates were resistant to 
Imipenem. The isolates resistant to imipenem were sensitive to 
Polymyxin and Colistin. BlaOXA-51, an intrinsic gene of Acinetobacter 
baumannii, was detected in all the 12 Acinetobacter baumannii strains of 
both Imipenem sensitive and resistant and not detected in the two 
Acinetobacter lwoffii strains. 
Conclusion :  
  During routine microbiological work, nonfermentative Gram 
negative bacilli other than Pseudomonas aeruginosa are not taken 
seriously and are considered as contaminants. But the rate of isolation of 
Acinetobacter indicates its role in nosocomial pathogen. Acinetobacter 
baumannii has a remarkable ability to upregulate or acquire resistant 
determinants. Acinetobacter baumannii is an emerging pathogen 
threatening the current antibiotic era.  
Key words: Acinetobacter, Speciation, Acinetobacter baumannii, 
Imipenem resistance, BlaOXA -51 gene. 






Acinetobacter species are gram negative, strongly aerobic, non 
fastidious, catalase positive, oxidase negative, non motile, encapsulated 
coccobacilli, sometimes difficult to decolorize, frequently arranged in 
pairs, with DNA  G + C content of  39 – 47 %1. 
Beijerinck in 1911 was credited with isolating a microbe 
representative of the genera from the soil and naming it Micrococcus 
calcoaceticus.The genera expanded and underwent numerous defining 
changes2. 
The genus was originally placed within the family Neisseriaceae 
but more recently moved to the family Moracellaceae, consist of 24 
named species and 9 unnamed species3. The name, Acinetobacter, comes 
from the Latin word for "motionless," because they lack cilia or flagella. 
 It is ubiquitous, widely distributed in soil, water, food, sewage & 
the hospital environment, survive on moist & dry surfaces3. Acinetobacter 
acidify glucose (may enhance its ability to invade devitalized tissue).  
Acinetobacter spp have the ability to use various sources of nutrition 
which accounts for its growth on routine laboratory media. This also 
explains its survival as an environmental pathogen. On Nutrient agar 
plate, colonies are 1 to 2 mm, nonpigmented, domed, smooth to slightly 
mucoid and opaque2.  
16 
 
However, routine identification in the clinical microbiology 
laboratory is not (yet) possible, they are divided and grouped into three 
main complexes3: 
• Acinetobacter calcoaceticus – baumannii complex : glucose 
oxidizing, non hemolytic (A. baumannii can be identified by 
blaOXA – 51 typing). 
• Acinetobacter lwoffii : glucose non saccharolytic, non 
hemolytic. 
• Acinetobacter hemolyticus : hemolytic. 
Newer methods of identification of different species2,4  
Methods include high resolution fingerprinting with AFLP, PCR 
based typing methods like randomly amplified polymorphic DNA PCR 
and Repetitive sequence based PCR (REP PCR), Multilocus sequence 
typing (MLST), Multilocus PCR followed by electrospray ionization 
mass spectrometry (PCR-ESI-MS), Matrix Assisted Laser Desorption 
Ionization- Time of Flight Mass Spectrometry(MALDI-TOF-MS) and 
Amplified ribosomal DNA restriction analysis (ARDRA). 
Transmission 
      Acinetobacter can spread to susceptible person by person to person 
contact or contact with contaminated surfaces. 
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Major infections due to Acinetobacter2,5,6  
  The respiratory system is the most common site for Acinetobacter 
infection because of its transient pharyngeal colonization of healthy persons 
and a high rate of tracheostomy colonization. Acinetobacter has been 
reported to cause community-acquired bronchiolitis and tracheobronchitis 
in healthy children. Other manifestation include Ventilator-associated 
pneumonia, urinary tract & bloodstream infection, Skin/wound infections, 
conjunctivitis, meningitis, endocarditis, CAPD-associated peritonitis.  
Risk factors6,7  
 Prolonged length of hospital stay, exposure to intensive care unit, 
mechanical ventilation, exposure to antimicrobial agents, recent surgery, 
invasive procedures and diminished host defenses like alcoholism, 
tobacco use, diabetes mellitus, renal failure, underlying pulmonary 
disease.  
Acinetobacter baumannii 
  Most species are not significant sources of infection. However, 
one opportunistic species, Acinetobacter baumannii , is found primarily in 
hospitals and poses a risk to people who are immunologically suppressed. 
Greater than 2/3 of Acinetobacter infections are due to A. baumannii, 
highly antibiotic resistant organism. A. baumannii has more recently 
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caused a range of infectious syndromes in military personnel injured in 
the Iraq and Afghanistan, and has become a successful pathogen in 
Afghanistan war7 .  
   Since the 1970s, the spread of multidrug-resistant (MDR) 
Acinetobacter strains among critically ill, hospitalized patients, and 
subsequent epidemics, have become an increasing cause of concern. 
Reports of community-acquired Acinetobacter infections have also 
increased over the past decade. A recent manifestation of MDR 
Acinetobacter that has attracted public attention is its association with 
infections in severely injured soldiers. Acinetobacter baumannii, has 
emerged as one of the most troublesome pathogens for health care 
institutions globally. Its clinical significance, especially over the last 15 
years, has been propelled by its remarkable ability to up regulate or 
acquire resistance determinants, making it one of the organisms 
threatening the current antibiotic era4. 
Mechanisms of resistance in Acinetobacter4,8 
 Enzymatic mechanism includes broad spectrum beta lactamase, 
carbapenemase, aminoglycoside modifying enzymes. Non enzymatic 
mechanism includes changes in the outer membrane protein, multidrug 
efflux pump, and alteration in the penicillin binding protein.       
19 
 
Documented mechanisms for resistance to carbapenems4,8 
  Production of beta lactamases in particular oxacillinase which is a 
class D beta lactamase in association with promoter gene sequence 
ISAba1. The most prevalent one is blaOXA-23. Metallo betalactamase (IMP, 
VIM), altered penicillin binding proteins and changes in the outer 
membrane protein especially the disruption of 33 kDa carO protein by IS 
elements also plays a role in carbapenem resistance. 
Biofilms enhancing the pathogenicity8 
 A. baumannii forms biofilms with enhanced antibiotic resistance 
and more recently, that a chaperone-usher secretion system involved in 
Pilus assembly affects biofilm formation. Acinetobacter commonly 
colonizes patients in the intensive care setting. Acinetobacter colonization 
is particularly common in patients who are intubated and in those who 
have multiple intravenous lines or monitoring devices, surgical drains, or 
indwelling urinary catheters. 
Diagnosis4 
  Infection or colonization with Acinetobacter is usually diagnosed 
by clinical culture of blood, sputum, urine, pus, body fluid, etc. 
Microbiologic cultures can be processed by standard methods on routine 
media. Acinetobacter baumannii isolates were presumptively identified 
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by using morphology of the colonies, Gram staining, Oxidase and 
Catalase reactions, growth at 42°C, and the API-20 NE System (Bio- 
Merieux, Lyon, France).  
Current trends in antibiograms2,5  
 Most A. baumannii are now resistant to Ampicillin, Carbenicillin, 
Cefotaxime and Chloramphenicol. Resistance to Gentamycin, 
Tobramycin and Amikacin is increasing. Fluoroquinolones, ceftazidime, 
Trimethoprim- Sulphamethoxazole, Doxycycline, Polymyxin B, Colistin, 
Imipenem and Meropenem may retain activity against nosocomial 
Acinetobacter. 
Treatment4,5,9  
  First line treatment is with Carbapenem antibiotics such as 
Imipenem, but carbapenem resistance is increasingly common. Other 
treatment options include Polymyxin, Tigecycline and Aminoglycosides. 
Colistin and Polymyxin B have been used to treat highly resistant 
Acinetobacter infections. The choice of appropriate therapy is further 
complicated by the toxicity of Colistin which is mainly renal. 
Acinetobacter isolates resistant to Colistin and Polymyxin B have also 




Preventive measures10  
   Acinetobacter can live on the skin and may survive in the 
environment for several days. Careful attention to infection control 
procedures such as hand hygiene, use of alcohol-based hand sanitizers, 
contact precautions, environmental decontamination, prudent use of 
antibiotics, healthcare worker education helps in reducing the infection.   
 As Acinetobacter is an emerging pathogen, this study is 
undertaken to find out the prevalence and its antimicrobial susceptibility 



















AIMS AND OBJECTIVES 
 
1. To know the prevalence of Acinetobacter in various clinical 
samples received in microbiology laboratory Thanjavur Medical 
College & Hospital. 
2. To study about different species of Acinetobacter prevalent among 
the various samples by biochemical tests.       
3. To assess the in vitro susceptibility and resistance pattern of 
Acinetobacter. 

























                 REVIEW OF LITERATURE 
Historical review  
The history of the genus Acinetobacter dates back to the early 20th 
century. In 1911, Beijerinck, a Dutch microbiologist, described an 
organism named Micrococcus calcoaceticus. It was isolated from soil by 
enrichment in a calcium - acetate - containing minimal medium. In the 
following decades, similar organisms were described and assigned to 
atleast 15 different genera and species. It includes Diplococcus mucosus, 
Micrococcus calcoaceticus, Alcaligenes haemolysans, Mima polymorpha, 
Herellea vaginicola, Bacterium anitratum, Moraxella lwoffi, Moraxella 
lwoffi var. glucidolytica, Neisseria winogradskyi, Achromobacter 
anitratus and Achromobacter mucosus 2,4 . 
In 1954 Brisou and Prevot proposed the current genus designation, 
Acinetobacter, to separate the nonmotile from the motile microorganisms 
within the genus Achromobacter. This genus was a heterogenous group 
inclusive of nonmotile, gram negative, catalase positive, and oxidase 
negative saprophytes distinguishable from other bacteria by their lack of 
pigmentation. The genus designation was not widely accepted until 1968. 






Baumann et al. published a comprehensive survey and concluded 
that the different species listed above belonged to a single genus, for 
which the name Acinetobacter was proposed. Their subclassification into 
different species based on phenotypic characteristics was not possible. In 
1971 the subcommittee on the Taxonomy of Moraxella and Allied 
Bacteria officially acknowledged the genus Acinetobacter. A 
transformation test was described (Juni 1972; Weyant et al.1996) and is 
still used for the genus level identification. This research techniques 
involves the conversion of auxotrophs to prototrophy. Since the organism 
classed within Acinetobacter were similar, a monotypic genus was 
proposed, Acinetobacter calcoaceticus, comprising two varieties, 
var.anitratus (formerly Herellea vaginicola) and var. lwoffi (formerly 
Mima polymorpha) (Juni 1984) 2,4 .  
 In the 1974 edition of Bergey’s Manual of systematic Bacteriology, 
the genus Acinetobacter was listed, with the description of a single 
species, Acinetobacter calcoaceticus. In contrast, in the “Approved List of 
Bacterial Names,” two different species, Acinetobacter calcoaceticus and 
Acinetobacter lwoffi were included, based on the observation that some 
Acinetobacter was able to acidify glucose whereas others were not. Based 
on the same property, the species A.calcoaceticus was subdivided into 
two subspecies or biovars, A.calcoaceticus bv. anitratus (formerly called 
Herellea vaginicola) and A.calcoaceticus bv.lwoffi (formerly called Mima 
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As currently defined, the genus Acinetobacter, comprises gram 
negative, strictly aerobic, nonfermenting, non fastidious, non motile, 
catalase- positive, oxidase-negative bacteria with a DNA G+C content of 
39% to 47% 1,4.Based on recent taxonomic data, it was proposed that 
members of the genus Acinetobacter should be classified in the new 
family Moraxellaceae within order Gammaproteobacteria, which includes 
the genera Moraxella, Acinetobacter, Psychrobacter, Pseudomonas and 
related organism 4,11.   
 A major breakthrough in the long and complicated history of the 
genus was achieved by Bouvet and Grimont in 1986. Based on DNA- 
DNA hybridization studies, they distinguished 12 DNA groups or 
genomospecies, some of which were given formal species names, 
including A. baumaninnii, A. calaoaecticus, A. haemolyticus, A. lwoffi, A. 
johnsonii, A. junii. Work done by Bouvet and Jeanjean, Tjernberg and 
Ursing, and Nishimura et al resulted in the description of further 
Acinetobacter genomic species. It included the named species 
A.radioresistens, which corresponds to Acinetobacter genomic species 12, 
as described by Bouvet and Grimont. Some of the independently 
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described species turned out to be synonyms e.g., A. lwoffii and 
Acinetobacter genomic species 9 or Acinetobacter genomic species 14, 
described by Bouvet and Jeanjean and Acinetobacter genomic species 13, 
described by Tjernberg and Ursing 4,5. 
Recently 10 additional Acinetobacter species were described. It 
included 3 species of human origin, A. parvus, A. ursingi and A. 
schindleri and 7 species isolated from activated sludge namely A. bayli, A. 
bouvetii, A. grimontii, A. gerneri, A. tjernbergiae, A. towneri, A. tandoii12. 
Three novel species (Acinetobacter soli, Acinetobacter beijerinckii 
and Acinetobacter gyllenbergi) were identified in 2008 and 2009 by two 
research groups. Recently Acinetobacter genomic species 10, 
Acinetobacter genomic species 11, Acinetobacter genomic species 3, 
Acinetobacter genomic species 13TU have been named Acinetobacter 
berezinae, Acinetobacter guilloriae, Acinetobacter pitti, Acinetobacter 
nosocomialis respectively. They can be phenotypically differentiated 
from other species within the genus Acinetobacter. At least 33 species 
within the Acinetobacter genus have so far identified, including 24 named 
species and 9 unnamed genomic species4. 
Four of the above listed species , namely A. calcoaceticus, A. 
baumanni, Acinetobacter genomic species 3, and Acinetobacter genomic 
species 13TU are very closely related and difficult to distinguish from 
each from each other by phenotypic properties. Therefore it has been 
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proposed to refer to these species as the A. calcoaceticus - A. baumannii 
complex13,14. This group of organisms, however comprises not only the 
three most clinically relevant species that have been implicated in the vast 
majority of both community acquired and nosocomial infections, but also 
A. calcoaceticus, which has been frequently recovered from soil and 
water, never been implicated in serious clinical disease. Since 
environmental species has given its name to the complex, the designation 
A. calcoaceticus- A. baumannii complex may be misleading and not 
appropriate if used in a clinical context.  










A. Calcoaceticus 1 ATCC 23055T 2,4,15 
A. Baumannii 2 ATCC 19606T 2,4,15 
A. Pitti 3 ATCC 19004 4,15 
A. Hemolyticus 4 ATCC 17906T 2,4,15 
A. Junii 5 ATCC17908T 4,15 
A.  gen spp 6 ATCC 17979 4,15 
A. Johnsonii 7 ATCC 17909 2,4,15 





A. Berezinae 10 ATCC 17924 4,15 
A. Guillouiae 11 ATCC 11171 4,15 
A. Radioresistens 12 IAM 13186T 2,4,15 
A. gen spp 13BJ/14TU ATCC 17905 4,15 
A. gen spp 14 BJ CCUG14816 4,15 
A. gen spp 15BJ SEIP 23.78 4,15 
A. gen spp 16 ATCC 17988 4,15 
A. gen spp 17 SEIP Ac87.314 4,15 
A. nosocomialis  ATCC 17903 15 
A. gen spp Between 1and 3 10095 4,15 
A. gen spp Close to 13 
TU 
10090 4,15 
A. venetianus  ATCC 3102 4,15 
A. ursingii  NIPH137T 4,15 
A. parvus  NIPH384T 4,15 
A. baylyi  DSM 14961T 4,15 
A. bouvetii  DSM 14964T 4,15 
A. towneri  DSM 14962T 4,15 
A. tandoii  DSM 14970T 4,15 
A. tjernbergiae  DSM 14971T 4,15 
A. gerneri  DSM 14967T 4,15 
A. soli  CCUG 59023T 15 
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A. beijerinckii  NIPH 838T 15 
A. gyllenbergii  NIPH 2150T 15 
Species Identification: 
Members of the genus Acinetobacter are gram-negative, catalase- 
positive, and oxidase negative. During periods of rapid growth 
(exponential phase) the organisms typically appear bacillary to 
coccobacillary 1- 1.5 by 1.5 – 2.5 microns in size. Notably they become 
more coccoid or diploccal as the cultures age (stationary phase). The 
colonies are 1- 2 mm in diameter (smaller than typical Enterobacteriaceae) 
and are typically domed, smooth to slightly mucoid and opaque. 
Pigmentation is usually greyish-white, although some strains may appear 
pale yellow. Hemolytic activity on blood agar is variable, although a 
diffusible brown pigment has been observed (Pagel and Seyfried 1976) 
when glucose has been added to the medium (Siau et al. 1998). 
Acinetobacters are nonlactose fermenters but they may produce a slight 
pinkish hue that could be mistaken for lactose fermentation2,16,17,18,19. 
 The Acinetobacters are nonmotile, but occasionally an odd 
twitching motility can be demonstrated (Lautrop 1961; Lautrop 1974; 
Barker and Maxted 1975). Acinetobacter baumannii strain M2 produces 
Type IV Pili (TFP) which play a role in natural transformation and 




Older cultures frequently capsulate, occasionally causing problems 
with destaining the crystal violet. For the most part, the species are not 
fastidious and capably grow on the standard nutritional medium used 
within the laboratory. Occasionally strains may be encountered that are 
fastidious, failing to grow in nutrient broth and forming smaller colonies 
on blood agar (Weyant et al.1996). Utilisation of carbohydrates varies 
considerably among the species. Nitrates are not reduced to nitrites. The 
ability to hydrolyse gelatin and urease is variable. They are strictly 
aerobic and are capable of growing at a wide range of temperature. 
However, it is observed that most clinical strains grow optimally at 37◦C, 
while the environmental isolates prefer lower temperatures. For clinical 
isolates, growth on MacConkey is variable and presenting as either 
colorless or light pink colonies2. 
Unlike Enterobacteriaceae, some species of Acinetobacter outside 
the  A.calcoaceticus-A.baumannii complex may not grow on Mac 
Conkey agar. Acinetobacter haemolyticus and several other currently not 
well defined species, such as Acinetobacter genomic species 6, 13 BJ, 
14BJ, 15 BJ, 16 and 17, may show haemolysis on sheep blood agar. This 
property is never present in isolates belonging to the A.calcoaceticus - 
A.baumannii complex. No single metabolic test distinguishes 




A reliable method for identification of Acinetobacter to the genus 
level is the transformation assay of Juni. It is based on the unique 
property of mutant Acinetobacter strain BD413 trpE27, a naturally 
transformable tryptophan auxotroph recently identified as A.baylyi to be 
transformed by crude DNA of any Acinetobacter species to a wild type 
phenotype21. 
Enrichment culture at low pH in a vigorously aerated liquid 
mineral medium supplemented with acetate or another suitable carbon 
source and nitrate as the nitrogen source has proven useful for the 
recovery of Acinetobacter from environmental and clinical specimens. 
Existing media for the isolation of Acinetobacter spp are either non 
selective, too inhibitory, inhibiting the growth of many Acinetobacter 
strains, allowing the growth of unwanted bacteria. To facilitate the 
isolation of Acinetobacter from mixed bacterial population, for rapid 
isolation and effective control of Acinetobacter infection, Leeds 
Acinetobacter medium was proposed. According to the results of MIC 
and viable counts, the concentration of antibiotics and other ingredients in 
this medium have been determined22. 
Identification of the Acinetobacter is often problematic for all but 
the reference laboratories. Unfortunately, the databases of most of the 
commercially available identification systems are variable in their ability 
to identify all isolates. Gerner - Smidt et al (1991) and Kampfer et al 
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(1993) have proposed various phenotypic schemes for identification. 
Review of the schema shows that they are not practical for the typical 
clinical laboratory owing to their requirement for a large number of 
biochemicals. 
The phenotypic identification scheme was first proposed by Bouvet 
and Grimont in 1986. It is based on 28 phenotypic tests. This 
identification scheme was refined in 1987 by the same authors. It includes 
growth at 37oC, 41oC, 44oC; production of acid from glucose; gelatin 
liquefication and assimilation carbon sources. 






OF test Arginine 
Chloram 
phenicol 
sensitivity 37○ C 42○C 
Acb complex - + + Saccharolytic + R 
A.lwoffi - + - NS - S 
A.hemolyticus + + - Saccharolytic (75%) + R 
A.junii - + - NS + R 
A.radio 
resistens - + - NS + R 
 






Pulse Field Gel Electrophoresis (PFGE) 
  PFGE extensively used, gold standard for Acinetobacter baumanni 
typing in some instance. Still it remains the reference method of choice. 
Laborious method, that requires several days before generating a typing 
result. The chromosomal fragments are separated by electrophoresis and 
digested with ApaI. The fingerprint profiles are visually compared or 
using specialized computer programs that also allow the storage of 
profiles in a database. Based on side-by-side comparison of molecular 
fingerprint patterns of a limited number of strains. Therefore 
interlaboratory comparison has always been a problematic one and it is 
not suited for population studies4,26,27. 
 
PCR based typing methods 
 Randomly amplified polymorphic DNA PCR – it involves 
amplification of random fragments of genonomic DNA with single 
primer with an arbitrary sequence. It has been used successfully to assess 
the strain relatedness of Acinetobacter isolates. 
Repetitive sequence based PCR - REP PCR uses consensus primers 





 Both methods do not require specialized equipments. Both are fast, 
easy and low cost methods that allow grouping of A.baumannii strains 
with various degrees of genotypic relatedness. However the 
discriminatory power of these methods are inferior to that of PFGE4,28. 
 
AFLP analysis:   
Amplified Fragment Length polymorphism - AFLP analysis was 
established in 1990. It is a highly sensitive DNA fingerprinting method. 
In this method, first DNA is digested with restriction enzymes, followed 
by selective amplification, electrophoretic separation of fragments and 
visualization. It is a expensive method, usually performed in a 
semiautomated procedure, with laser detection of fragments on a 
sequence platform. The resulting complex profiles are digitalized and 
analyzed with appropriate software. This high resolution fingerprinting 
method is useful for the characterization of Acinetobacter strains at the 
subspecies level and for outbreak investigation. It requires high level of 
standardization and extensive experience in interpretation of banding 
patterns. Hence, this method is restricted to reference laboratories and not 







Multilocus sequence typing was recently developed for 
Acinetobacter baumannii by Bartual and coworkers. It is based on the 
sequence of the conserved regions of the seven house keeping genes 
(gltA, gyrB, gdhB, recA, cpn60, gpi and rpoD). It is applied to 
Acinetobacter genomic species 13TU isolates also. The discriminatory 
power of the MLST system is comparable to that of both PFGE and AFLP. 
MLST is however expensive and laborious. Therefore not suited for 
routine outbreak analysis or other limited scale analysis of the 
epidemiology of Acinetobacter baumannii. It remains to be determined 
typing system and appropriate for the study of Acinetobacter species. It is 
suitable for global epidemiological study. It allow the recognition of 
epidemic, multiresistant and virulent A.baumannii clones and the 
monitoring of their national and international spread4,27,28. 
 
PCR – ESI – MS 
 Multilocus PCR followed by Electrospray ionization mass 
spectrometry is used for species identification of Acinetobacter 
baumannii and to determine clonality. The six bacterial house keeping 
genes – trpE, adk, efp, mutY, fumC and ppa are amplified from each 
isolate. The amplified products are desalted and purified and then mass 
spectra are determined. The system was established using 267 
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Acinetobacter isolates collected from infected and colonized soldiers in 
an outbreak in the military health care system associated with war in Iraq, 
outbreaks in European hospitals and culture collections. Correlation with 
PFGE typing was good. Advantages of PCR-ESI-MS are, it is very fast 
taking only 4 hours, providing typing results on a time scale which is not 
achievable with most other system29. 
 
MALDI-TOF -MS 
 Matrix-Assited Laser Desorption Ionization-Time of Flight Mass 
Spectrometry has been developed for the rapid identification of pathogens. 
Promising results with MALDI-TOF MS obtained for species 
identification of 552 well characterized Acinetobacter strains representing 
15 different species. For MALDI-TOF-MS , bacteria are cultured for 24 
hours at 37◦C on MacConkey agar and extracts are prepared. For 
identification of isolate, the row spectra are compared with those in the 
Biotyper database and log of greater than 2.3 to represent a secure species 
identification. Spectra are acquired with a microflex LT mass 
spectrometer and recorded in the positive linear mode at a laser frequency 
of 20 HZ, ion source 1 voltage of 20 kv, ion source 2 voltage of 8.5 kv 
and mass range from 2000 to 20,000 kDa. Reference specra of newly 
created main spectra is added to the original Biotyper database. To 
evaluate the spectrum variation within each strain, to estimate the mass 
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spectral variance of biological replicates, a principal component analysis 
is performed. It provides similar results in good concordance with 
rep-PCR. The accuracy and speed of data acquisition can be achieved 
using MALDI-TOF MS. It can be successfully used in routine clinical 
microbiology for real time identification of nosocomial outbreaks from 




 Amplified ribosomal DNA restriction analysis is used for the 
identification of the Acinetobacter genomic species. Restriction analysis 
with the enzyme AluI, CfoI, MboI, RsaI and MspI of the enzymatically 
amplified 16 rRNA genes is used to identify all species except genomic 
species 4, 5,7 17,10,11. It is a rapid and reliable method for the 
identification of the Acinetobacter genomic species including the closely 
related DNA groups 1, 2, 3 and 13. ARDRA helps to elucidate the 
ecology and clinical significance of the different species of this genus. 
Since ARDRA use universal 16srRNA gene primer, it is applicable to 
identification of most bacterial species. ARDRA is less prone to 
contamination problems than PCR, since the use of cultured organism 




Partial rpoB sequence analysis 
 The degree of polymorphism of house keeping protein gene 
encoding genes such as recA, gyrB, rpoB genes are higher than that of the 
non protein encoding 16s rDNA gene. Sequence analysis of this genes 
provides a method with a better level of resolution for the identification 
and taxonomic classification of various bacterial species. Sequence 
analysis of 4 zones of the RNA polymerase beta subunit gene and its 
flanking space is a useful molecular method for identification of 
Acinetobacter species. Sequence analysis of the highly discriminative 
Zone 1, spanning 352 bp between position 2901 and 3250 on the rpoB 
gene in particular is used to represent a reliable and rapid identification 
method for Acinetobacter species. rpoB gene sequence analysis has been 
suited for both collection of Acinetobacter reference strain and a 
collection of Acinetobacter clinical isolate15 
 
Manual and semiautomated commercial identification system 
 Species identification with manual and semiautomated 
commercial identification system are currently used in diagnostic 
microbiology. They are API 20NE, Vitek 2, Phoenix and MicroSan 
WalkAway Systems. Substrates used for bacterial identification system 
have not been tailored specifically to identify Acinetobacter. Three 
clinically relevant members of the A. calcoaceticus-A.baumannii complex 
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cannot be separated by these systems. A. baumannii, A. genomic species 
3, and Acinetobacter genomic species 13TU are uniformly identified as A. 
baumannii.   
 
Natural Habitats 
 Acinetobacter are part of the human skin flora. In an 
epidemiological survey performed to investigate the colonization of 
Acinetobacter in human skin and mucous membrane, upto 43% of non 
hospitalized individuals were found to be colonized with Acinetobacter. 
A.lwoffii (58%),A. johnsonii(20%), A. junii (10%) and Acinetobacter 
genomic species 3(6%) were most frequently isolated species. In a similar 
study carrier rate of 44% was found among healthy volunteers, out of 
which A.lwoffii (61%), Acinetobacter genomic 15BJ (12%), 
A.radioresistens (8%), and Acinetobacter genomic species 3 (5%) were 
more prevalent species33. 
 Dijkshoorn et al. studied fecal carriage of Acinetobacter, found 
that carrier rate of 25% among healthy individuals with A.johnsonii and 
Acinetobacter genomic species 11 predominating. In contrast, 
A.baumannii which is the most predominant nosocomial species was 
found rarely on human skin and human feces and Acinetobacter genomic 




Griffith et al.investigated the nares of healthy U.S. soldiers. Since 
he did not use enrichment culture, he did not find Acinetobacter at all. In 
the subsequent study, Griffith et al did not detect skin carriage of the A. 
Calcoaceticus-A. baumannii complex among 102 U.S Army soldiers.The 
reason was again he performed culture without enrichment and with an 
extremely long transport time35. 
 Chu et al. found 53% of medical students and new nurses to be 
colonized with Acinetobacter in summer versus 32%in winter. This is due 
to, seasonal variability in skin colonization contributing to seasonal 
variation in the prevalence of A.baumannii in clinical samples36,37. 
 Although various Acinetobacter species were isolated from 
animals, A. baumannii was occasionally found as an etiological agent in 
infected animals. A.baumannii was recovered from 22% of body lice 
sampled from homeless people. This finding might result from clinically 
silent bacteremia in these people38. 
 Berlau et al. investigated vegetables in the United Kingdom and 
found that 30 of 177 vegetables (17%) were positive for Acinetobacter. 
The predominant species were A. baumannii and Acinetobacter genomic 
species 11 (each at 27%) followed by A.calcoaceticus and Acinetobacter 
genomic species 3 (each at 13%), while Acinetobacter genomic species 




Houang et al.found Acinetobacter in 22 out of 60 soil samples in 
Hong Kong. The most frequently isolated species were Acinetobacter 
genomic species 3(27%) and A.baumannii 23%, with only one 
A.calcoaceticus. 
Recently described Acinetobacter species namely A. baylyi, A. 
bouvetii, A.grimontii, A.tjernbergiae, A.towneri, and A. tandoii were 
isolated from activated sludge. Obviously they are environmental species 
and never been found in humans. A. schindleri and A. ursingii have been 
recovered from human species only. A. parvus was found in humans and 
also in dogs12. 
In conclusion, Acinetobacter species seems to be distributed widely 
in nature. A.calcoaceticus is found in water, soil and on vegetables. 
Acinetobacter genomic species 3 is found in soil, water, vegetables and 
human skin. A.johnsonii found in water, soil, human skin and feces. 
A.lwoffi and A.radioresistens are found in human skin. Acinetobacter 
genomic species 11 found in water, soil, vegetables and human intestinal 
tract. In Europe, the carrier rate of A.baumannii in the community is 
rather low. A.baumannii does not appear to be a typical environmental 
organism, although it has been found in soil samples in Hong Kong and 






 Acinetobacters are saprophytic and ubiquitous. They can be found 
throughout the natural and hospital environment on a wide range of dry 
and moist inanimate surfaces (Getchell-White et al 1989; Towner et 
al.1991). 
Acinetobacter isolates accounted for 4.25% of the total number of 
organism isolated24. Incidence of Acinetobacter among non fermentor is 
Acinetobacter baumannii - 24.87 %, Acinetobacter lwoffii – 8.47%. 
Imipenem resistance of Acinetobacter in Asian countries from 2008-2009 
was 67%. The rate was especially high in Malaysia (86.7%), Thailand 
(81.4 %), India (85.7 %) and China (88.9%)40. 
 In large surveillance studies from the United states, about 5 to 
10% of ICU acquired pneumonia were due to A.baumannii. Overall crude 
mortality rate of A.baumannii bloodstream infection was 34 to 43% in 
ICU and 16.3% outside the ICU. A.baumannii was the 10th most common 
etiologic agent responsible for 1.3% of all monomicrobial nosocomial 
bloodstream infections. A.baumannii blood stream infection had the third 
highest crude mortality rate in the ICU next to Pseudomonas aeruginosa 
and Candida sp infection. The crude mortality of A.baumannii blood 





Outbreak of infections are associated with spread of unique strain 
and due to contaminated respiratory therapy equipment, bedding 
materials, intravascular access devices and transmission via the hands of 
hospital personnel41. Recently European investigators suggested that 
similar to the epidemiology of methicillin resistant staphylococcus aureus, 
a few epidemic of A.baumannii strains may be involved in outbreaks at 
various institutions as well as in international spread41,42. 
Wilks et al reported a recent outbreak of multidrug resistant 
Acinetobacter infection, with environmental contamination found on 
curtains, laryngoscope blades, door handles, mops, patient lifting 
equipment and keyboards. This emphasize the need for special attention 
to disinfection of shared items and extra caution with wound care and 
respiratory care procedures. One or more epidemic Acinetobacter clones 
often coexist with endemic strains. This makes it difficult to detect and 
control transmission4. 
Abbo et al.studied 118 patients with multidrug-resistant 
Acinetobacter infection in Israel and found 10 different PFGE-typed 
clones. He also found many clusters of patients with no common source 
identified, despite molecular testing and extensive investigation43. 
Nemec et al. used ribotyping and amplified fragment-length 
polymorphisms for demonstrating the genetic relatedness of 
Acinetobacter isolates in Western Europe. Investigators used PFGE to 
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demonstrate the inter institutional spread of carbapenem resistant 
Acinetobacter infection among acute care hospitals in New York, 
Argentina, the United kingdom, and the Iberian peninsula4. 
Gales et al used PFGE to demonstrate the spread of epidemic 
Acinetobacter clones between Argentina and Brazil44. 
Multidrug resistant Acinetobacter deep wound infection, 
osteomyelitis, bacteremia and respiratory infections have been reported 
among military personnel with traumatic injuries during the conflicts in 
Iraq and Afghanistan41. 
Brink and colleagues found that 30% of A.baumannii bloodstream 
isolates in south Africa are carbapenem resistant, 40% are Cefipime And 
Pipercillin-Tazobactam resistant and 30% are Ciprofloxacin and 
Levofloxacin resistant45 . 
The first Australian outbreak of hospital acquired A.baumannii was 
in Western Australia. The isolates were resistant to Gentamicin, 
Cephalosporins, Ciprofloxacin and Ticarcillin. Molecular epidemiological 
analysis found that 11% of staff hand samples were positive for the same 
strain of A.baumannii as that causing patient infection46. 
Aygun et al. 2002 studies have documented that hospital 
environments, such as intensive care units (ICU), can harbor carbapenem 
resistant A.baumannii. Only after closing the affected ICU and thorough 
cleaning of the environment and equipment with hypochlorite and 
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terminal disinfection, the resistant were eliminated2. 
Brooks et al. 2002 documented that pan resistant acinetobacters 
could be recovered from the surfaces of dispensers of hand soap 
containing 2.0 percent chlorhexidine2. 
Taplin et al. 1963 considered Acinetobacters as part of the 
commensal flora of man and other animals, where they occasionally 
present as opportunistic pathogens. As commensals, they have been 
isolated from axillae, groin, digital webs, and other external fossa of 
about 25 percent of population2. 
Larson et al. 1986 have demonstrated sustained carriage on the 
hands of health workers. Larson determined that Acinetobacter was the 
most common gram-negative organisms carried on the skin of hospital 
personnel. Members of the genus have been isolated from practically 
every type of patient specimen. This ubiquity often presents problems for 
the clinician. Therefore, careful evaluation of the role of an isolate to an 
infectious process is required2. 
Interestingly it appears that the genomic distribution of the various 
Acinetobacters differs greatly throughout the diverse hospital 
environments. A.baumannii is the species isolated most frequently. 
Assimilation test have identified 19 biotypes (Bouvet and Grimont 




As with many other genera, many different typing systems have 
been devised to segregate the various members of this genus. Refer to 
Bouvet (1991) for a review of early attempts at typing schema. 
Conventional methods have presented problems that have precluded their 
adaptation. These methods have included biotyping (Bouvet et al. 1990), 
phage-typing (Vieu et al.1979), serotyping (Traub and Leonhard 1994) 
and bacteriocin typing (Andrews 1986)2. 
Currently, several molecular methodologies have been developed 
and used within the clinical setting for the investigation of nosocomial 
outbreaks, although it is important to note that no particular system has 
been accepted as the gold standard. These technique have included 
plasmid profile analysis (Gerner-smidt and Tjernberg 1993;Seifert et 
al.1994), restriction endonuclease digestion and pulse field gel 
electrophoresis of total chrosomal DNA (Gouby et al 1992; Struelens et 
al.1993; Liu and Wu 1997; Grundmann et al 1997), random amplified 
polymorphic DNA profiles(Graser et al.1993; Struelens et al1993), 
ribotyping(Gerner-Smidt 1992; Bernards et al 1997), cell envelope and 
outer membrane protein profiles(Dijkshoorn et al.1987a,1987b), and 
multilocus enzyme electrophoretic typing(Thurm and Ritter 1993)2. 
Ackermann et at: strain specificity has been demonstrated for 




Typically, most of the bacteriophages are lytic and are 
range-restricted to the original strain of Acinetobacter from which they 
were isolated2. 
 
Virulence and pathogenic factors 
Usually Acinetobacter are opurtunistic pathogens, they have 
components that are capable of enhancing their virulence in debilitated 
individuals such as those in burn or intensive care unit and those who 
have received multiple antimicrobial agents9.. Perhaps the most important 
and similar to other gram negative organisms is the presence of endotoxin. 
Endotoxin is a lipopolysaccharide (LPS) moiety of the outer membrane 
and in which the toxic lipid component, lipid A, is embedded. It has been 
demonstrated that the LPS is responsible for toxicity in mice and 
pyrogenicity in rabbits. Endotoxin is considered partially responsible for 
the febrile response during septic episodes. For Acinetobacter pneumonia, 
Obana demonstrated an enhanced virulence in the presence of mixed 
infections with other bacteria species in the mouse model. Obana’s study 
could not identify conclusively the definitive nature of this enhancement2. 
 The research by Borneleit and Kleber on the matrix of the cell 
wall and outer membrane demonstrates special properties capable of 




Fimbriae have been documented that they are potentially capable of 
facilitating adhesion to human epithelial cells2. 
Anstey et al 1992: A polysaccharide capsule has been described 
that perhaps limits phagocytosis 
Wendt et al 1997: This capsule certainly aids the bacteria to survive 
under dry condition. 
Obana et al 1985; Borneleit and Kleber 1991: The above properties 
in conjunction with proteins layers and slime also potentially enhance the 
virulence of the organism. 
Interestingly, it has been noted that certain strains have been shown 
to produce siderophores (e.g.aerobactin) and iron repressible 
outer-membrane receptor proteins (Smith et al 1990; Echenique et al 




 Generally Acinetobacter are not fastidious and are capable of 
surviving in various environmental niches. Most importantly they are 
adapt at acquiring resistance to multiple antibiotics. Fortunately, most 
isolates are simply colonizers in healthy individuals (Bergogne-Berezin 
and Towner 1996; Cisneros et al 1996). However determing the clinical 
significance of a particular isolate can be problematic for the clinician, 
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particularly for intensive care patients and others with extensive surgical 
or antibiotic intervention. The opportunistic potential of this genus for 
causing hospital acquired infections is well documented. 
Corbella et al (1996) studies have shown that the digestive tracts of 
patients within ICU often serve as reservoirs for multiresistant 
A.baumannii strains involved in hospital outbreaks. 
The respiratory tract is the prominent site for hospital acquired 
infections, with endotracheal tubes frequently implicated. Additionally 
isolates found from the urinary tract, wounds and catheter sites may 
eventually lead to septicemia (Bergogne-Berezin and towner1996; 
Bernards et al 1997; Cisneros et al 1996; Seifert et al 1995) 
Less frequently, members of the genus have been associated with 
arthritis, endocarditis, meningitis, osteomyelitis, peritonitis related to 
continuous ambulatory peritoneal dialysis and ventilator related 
pneumonias. 
A. baumannii is the species most often responsible for hospital 
acquired infections. A. lwoffii has been more commonly associated with 
meningitis than other Acinetobacter species. A. ursingii has been shown 
to cause blood stream infections in hospitalized patients. A. juni is a rare 
cause of ocular infection and bacteremia, particularly in paediatric 
patients. A case of community acquired Acinetobacter radioresistens 
bacteremia in an HIV positive patient has also been reported. A. 
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schindleri have been recovered from a variety of human specimens 
(vaginal, cervical, throat, nasal, ear, conjunctiva, and urine) but are 
mostly regarded as clinically nonsignificant5. 
Risk factor for colonization or infection with multidrug resistant 
Acinetobacter species include prolonged length of hospital stay, exposure 
to an intensive care unit, receipt of mechanical ventilation, colonization 
pressure, exposure to antimicrobial agents, recent surgery, invasive 
procedures and underlying severity of illness42. 
 
Genetic resistance2 
 Transformation is probably not a significant event among the 
Acinetobacters. The process was first demonstrated by Juni and Janik 
with A. calcoaceticus strain BD4 and its microencapsulated trpE27 
mutant derivative BD413. Juni demonstrated that the transformation of 
strain BD413 trpE27 to the wild phenotype could be used as the basis of 
the genetic test for identifying members of the genus. The ease with 
which strain BD413 can be transformed, has been used with a wide range 
of advanced molecular procedures, allowing the detailed fine structure 
genetic investigations of the chromosomal organization and metabolic 
regulation of this strain. 
 Strain specificity appears to exist with regards to transduction. 
Using P78, a temperate phage, Herman and Juni demonstrated a low 
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frequency generalized transduction with its specific host, while failing to 
lysogenize 389 other strains of Acinetobacter. 
 Towner and Vivian (1976) and Hinchliffe and Vivian (1980) 
demonstrated that conjugation could occur with a broad host range of 
plasmids using Acinetobacter strain EBF 65/65. Although very little is 
known of the mobilization events , the system has been important for the 
mapping of mutations on the circular chromosomal linkage group in 
strain EBF 65/65. 
 Plasmids and transposons are perhaps the most interesting to 
researchers and clinicians and probably serve as important role in the 
biology of Acinetobacter species. It has been observed that more than 
80% of Acinetobacter isolates appear to carry multiple indigenous 
plasmids of variable size. Unfortunately involving plasmids and 
transposons have been riddled with problems most likely due to 
difficulties in lysing organism’s cell wall. Transposons, as opposed to 
plasmids may be more important to the development of antibiotic 
resistance in clinical isolates. This observation may be due to the lack of a 







Mechanism of Antibiotic Resistance 
 Treatment for Acinetobacter infections involve the use of beta 
lactams, aminoglycosides, and quinolones. The increased use of 
antibiotics, however resulted in a widespread emergence of antibiotic 
resistant strains. Carbapenem, a class of beta lactam, with a broad 
spectrum of antibacterial activity, have been widely used as the mainstay 
of treatment for infections caused by such antibiotic resistant strains. Now, 
Acinetobacter strains resistant to carbapenems have also emerged 
worldwide rapidly. Different levels and patterns of antimicrobial 
susceptibilities have been found among different Acinetobacter species. 
Several studies reported a higher occurrence of multidrug resistance in A. 
baumannii compared with the non A. baumannii species15.  
Fournier et al described the broad resistance pattern of 
Acinetobacter baumannii. He performed whole genome sequencing of a 
clinical epidemic Acinetobacter baumannii strain found in France 
(AYE).AbaR1, an 86-kb resistance island, one of the largest to be 
described so far, was identified. Genomic islands containing resistant 
markers are referred to as resistance islands. Resistant islands are found 
mainly in gama proteobacteria like shigella flexneri, vibrio cholaera, 





Among the 88 predicted open reading frames (ORFs) within the 
genomic region, 82 were predicted to be originated from the other gram 
negative organisms, such as Pseudomonas species, Salmonella species 
and Escherichia coli. The G + C content of this region was 52 %, whereas 
the G + C content of the remaining chromosomes was 38.8%, indicates 
that the genome was more likely a foreign source. Overall 52 resistance 
genes were identified , out of which 45 (86.5 %) were localized to the 
AbaR1 resistance island. The genetic surroundings of these resistance 
determinants provided more evidence for genetic promiscuity, the 
presence of genes associated with genomic instability were integrases, 
transposases and insertion sequence. No plasmid markers were identified 
in the resistance hot spot. Among the three plasmids found within the 
AYE strain, none contained any known resistance marker7. 
The resistant AYE strain was compared to the susceptible A. 
baumannii strain from the same geographic region (SDF) ,a structure 
AbaG1 was identified in the homologous ATPase like ORF.But it was 
devoid of resistance determinants.Detailed sequence comparison of the 








Enzymatic mechanism:  
In Acinetobacter, the most prevalent mechanism of beta lactam 
resistance is enzymatic degradation by beta lactamase. 
Class B beta lactamases (metallo- beta- lactamases, MBLs) 
confers higher level of Carbapenem resistance and also resistance to all 
other beta lactams except aztreonam. MBLs are different from other 
classes of beta lactamases by being susceptible to EDTA inhibition due to 
the requirement of Zinc ions in the active site15. 
Several Inosine Monophosphate dehydrogenase (IMP) - (IMP-1, 
IMP-2, IMP-4, IMP-5, IMP-6, IMP-8, IMP-11) and Verona Integron 
encoded MBL (VIM) - (VIM-1, VIM-2, VIM-4, VIM-11) variants have 
been detected among the isolates of A. baumannii-A. calcoaceticus 
complex47. 
 SIM-1 was first described in A. baumannii strain. Studies reported 
a lower level of carbapenem resistance conferred by SIM-1 compared 
with that of IMP and VIM variants. So far, blaSIM-1-like  genes have been 
found only among Acinetobacter isolates from Korea48. All different 
variants of blaIMP,  blaVIM,  and blaSIM  in A.baumannii isolates have been 
located on class 1 integrons47. 
NDM-1 has been mainly found in Enterobacteriaceae isolates 
particularly from the Indian subcontinent, but it has also been detected in 
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isolates of A.baumannii from India as well as other parts of the world. 
Resistance to carbapenems are mediated by the coexistence of blaNDM-1, 
blaOXA23, and blaIMP. It has been detected in pan-drug resistant isolates of 
A. baumannii from China. Recently NDM-2, a variant of NDM-1 with 
only one amino acid substitution, has been described in an A.baumannii 
isolate recovered from a patient transferred from Egypt to Germany49.           
 Class C beta lactamase: Inherent to all Acinetobacter strains are 
chromosomally encoded Class C beta lactamases-AmpC 
cephalosporinase. It is also known as Acinetobacter derived 
cephalosporinases (ADCs). Unlike AmpC enzymes found in other gram 
negative organisms, inducible AmpC expression does not occur in 
A.baumannii.This enzyme when overexpressed hydrolyze most 
penicillins, cephalothin, cefazolin, cefoxitin, ceftazidime, and beta 
lactamase inhibitor/ beta lactam combinations, but generally not cefipime 
or carbapenems. So far, AmpC cephalosporinase have been identified in 
only a few Acinetobacter species namely A. baumannii, A. pittii, 
A.baylyi50.  
Phylogenetic analysis demonstrated that AmpC cephalosporinases 
from A.baumannii and A.pittii are more closely related to each other, 
comparing to the variants produced by other genera of bacteria. The 
AmpC cephalosporinase from A.baylyi (designated as ADC-8) was less 
homologous to ADC-5 of A.pittii and ADC-7 of A.baumannii. But the 
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phylogenetic proximity of all the ADC cephalosporinases, including 
ADC-8, evolved from a common ancestor. Normally the blaADC genes in 
A.baumannii are normally expressed at basic levels. The key determinant 
in regulating overexpression of AmpC cephalosporinase in A.baumannii 
is the presence of an upstream Insertional (IS) element known as 
ISAba150. The main mechanism responsible for resistance to ceftazidime 
and other extended spectrum cephalosporins in A. baumannii is ADC 
enzymes.Till date about 44 blaADC genes have been identified10,15. 
 Class D beta lactamases - OXA type beta lactamases are 
pencillinases that are able to significantly hydrolyze aminopenicillins 
(ampicillin and amoxicillin) and carboxypenicillins (carbencillin and 
ticarcillin). Some of the OXA-type beta lactamase variants also have the 
ability to hydrolyse extended spectrum cephalosporins. The other variant, 
described as OXA-type carbapenemases, are able to hydrolyze 
carbapenems. Most of the extended spectrum OXA type beta lactamases 
are point mutation derivatives of related narrow spectrum enzymes. So 
far identified OXA-type carbapenemases are remotely related to the 
non-carbapenem hydrolyzing OXA-type beta lactamases51. 
OXA-20, OXA-21 and OXA-37 are the only narrow-spectrum 
OXA type beta lactamases have been so far identified in Acinetobacter 
isolates. The gene for these enzymes are identified in the form of gene 
cassettes inserted into the class 1 integrons. Till now, none of the 
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extended spectrum OXA-type beta lactamases has been found in any 
Acinetobacter species. In contrast, OXA type carbapenemases, with the 
exception of blaOXA-48, have been exclusively found among the isolates of 
the genus Acinetobacter51. 
 
 OXA-58 oxacillinase was the first enzyme identified in 
Acinetobacter baumannii isolate in France8. The first identified OXA type 
enzyme with carbapenem hydrolyzing activity was from a clinical 
Acinetobacter baumannii strain isolated in 1985 from Edinburgh. It was 
initially named as ARI-1.This plasmid encoded reistance determinant was 
found to be transferable.The gene was later sequenced and named as 
blaOXA-2352.  
The OXA type carbapenemase genes in Acinetobacter species can 
be divided into four phylogenetic subgroups - blaOXA-23-like, blaOXA-24-like, 
blaOXA-51-like and blaOXA-58-like plus five discrete genes - blaOXA-134, blaOXA-104, 
blaOXA-143, blaOXA-164, and blaOXA-182. The variants within each of the four 
main subgroups have nucleotide sequence identities of greater than 96%. 
Whereas the nucleotide sequence identities of the variants from different 
subgroups, including the discrete genes, range from 46% to 76%. 
Exception include a 92% nucleotide sequence identity between blaOXA-143 
and blaOXA-182 and 88% nucleotide sequence identity between blaOXA-24-like 




The OXA type carbapenemase shows a low hydrolytic activity 
against imipenem and meropenem. It also hydrolyse the narrow spectrum 
penicillins (benzylpenicillin, ampicillin, piperacillin, ticarcillin) and 
cephalosporins (cefalotin, cefaloridine) efficiently. The extended 
spectrum beta lactams (ceftazidime, cefotaxime) and aztreonam are not or 
very poorly hydrolysed by these enzymes53. 
It has been discovered that blaOXA-51 like gene is associated with 
carbapenem resistance in isolates with an adjacent copy of insertion 
sequence ISAba1. 
 
Role of ISAba elements 
 Insertion sequence are the smallest of size less than 2.5 kb. It is 
the most abundant genetic element capable of independent mobility in 
microbial genomes. Insertional sequence are responsible for the 
occurrence of insertional mutations, genome rearrangements, enhanced 
spread of resistance and virulence determinants within species54. 
Several IS elements are commonly and exclusively detected in the 
genus Acinetobacter. ISAba1 is a strong promoter, resulting in over 
expression of the intrinsic blaADC and blaOXA-51-like and the acquired 
blaOXA-23-like genes of Acinetobacter baumannii. ISAba1 acts similarly with 
other resistant genes such as sulI1 and blaOXA-58-like. ISAba2, ISAba3, IS18 
and ISAba825 also provide strong hybrid promoters for blaOXA-58-like. 
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ISAba4 is responsible for an enhanced expression of blaOXA-23-like55 
.
Sequence analysis of the genetic environment of blaNDM-1 in 
Acinetobacter baumannii isolate from Germany revealed a chromosomal 
occurrence of blaNDM-1 on a 10.5 kb genetic structure bracketed by two 
copies of ISAba125. The upstream ISAba125 provides a strong promoter 
for blaNDM-1 expression. The blaADC gene in the fully sequenced 
Acinetobacter baumannii strain ACICU is also preceded by an ISAba125 
element56.   
 
Nonenzymatic  mechanism 
 Non enzymatic mechanism is also responsible for beta lactam 
resistance, including carbapenem resistance . Non enzymatic 
mechanisms10 are 
 1. Changes in the outer membrane proteins (OMPs) 
 2. Multidrug efflux pumps. 
3. Alterations in the affinity or expression of penicillin binding protein 
 
Changes in OMPs & porins 
Changes in porins or OMPs reduces the transport of beta lactam 
into the periplasmic space, this in turn reduces the access to PBPs. 
Comparing to the susceptible ones, the outer membrane in MDR 
Acinetobacter baumannii is less permeable to antimicrobial agents. 
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Alteration in permeability disturbs the beta lactam assimilation into the 
periplasmic space, this leads to weaker activity of antibiotics8. 
 Several porins including the 33-kDa CarO protein constitute a 
pore channel for influx of carbapenems. This might be involved in the 
resistance of carbapenem. The distruption of OMP genes by ISAba10 
element may sometimes lead to the inactivation of the OMPs like CarO. 
This reduces the extent of which the antibiotic enters the cell. The 
chromosomal locus containing the carO gene was cloned from the clinical 
isolates and it was characterized. It showed, that only a single copy of 
carO, present in a single transcriptional unit was present in the 
Acinetobacter baumannii genome.The carO gene encodes a polypeptide 
of 247 aminoacid residues along with a typical N-terminal signal 
sequence and predicted transmembrane beta barrel topology57. 
Recent studies revealed that the disruption of the carO gene by the 
IS elements such as ISAba1, ISAba125 or ISAba825. This results in loss 
of activity of carO OMP leading to carbapenem resistance in 
Acinetobacter baumannii58. Recent reports of outbreaks caused by 
carbapenem resistant phenotypes and their characterization revealed that 
the loss or reduction of porins such as OMPs of 22-29 kDa , 47, 44, and 
37 kDa and one of 31 - 36 kDa. This substantiates the findings of 
previous investigations on OMPs. Gene expression studies along with 
phenotypic characterization of membrane proteins clarifies the role of 
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membrane permeability in beta lactam resistance57,58.  
  The major protein present in the outer membrane of 
Acinetobacter baumannii does not belong to the high permeability 
trimeric porin family. The pore size of the OmpAAb channel is about 2nm 
in diameter. OmpAAb produce very low pore forming activity. It is about 
70 fold lower than that of OmpF of E.coli. The outer membrane 
permeability to cephalothin and cephaloridine is about 100 fold lower 
than that of E.coli k-12. When the OmpAb gene is deleted, the 
permeability of cephalothin and cephaloridine in Acinetobacter 
baumannii is decreased 2 to 3 fold. The low permeability of this porin 
together with the presence of beta lactamase and multidrug efflux pumps, 
such as AdeABC and AdeIJK result in high level of intrinsic resistance to 
a number of antibiotics59. 
 Three porins namely the carbapenem associated OMP carO, 
Omp33/36 and a 43-kDa porin also called OprD homologue facilitate 
carbapenem diffusion through the Acinetobacer baumannii outer 
membrane. These porin channels expression are reduced in several 
carbapenem resistant strains. Among the three porin channels, the OprD 
homologue is more responsible for the formation of carbapenem specific 






 Among the well studied mechanisms of resistance in 
Acinetobacter baumannii, efflux pumps are the one, by which the 
bacterial cells overcome the action of antibiotics by expelling them out. 
According to Fournier et al., 2006 the 3.9 Mb genome of 
Acinetobacter baumannii AYE is reported to harbor 46 open reading 
frames (ORFs) encoding putative efflux pumps of different families. It 
has been reported that, the overexpression of efflux pump in the antibiotic 
resistant strains provides the evidence for the role of efflux pumps in 
making the bacteria multi drug resistant7. 
 Till date five classes of efflux pumps have been reported to be 
present in Acinetobacter baumannii. They are7 
 1. ATP binding cassette (ABC) 
 2. Major facilitator superfamily (MFS) 
 3. Multidrug and toxic compound extrusion (MATE) 
 4. Resistance nodulation cell division (RND) 
 5. Small multidrug resistance (SMR) 
The efflux systems in Acinetobacter baumannii that are completely 
characterized functionally includes61  
 RND type – AdeABC, AdeFGH, AdeIJK  
 MATE type – AbeM 
 MFS type – CraA. 
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According to Iacono et al., and Srinivasan et al : They have only 
partial knowledge on the function of ABC and SMR efflux pumps. 
 
RND type efflux pump8 
The RND type efflux pumps that are commonly found in Gram 
negative bacteria are usually tripartite in nature. It consist of three protein 
components. They are 
1. Cytoplasmic protein 
2. Intermembrane or membrane fusion protein (MFP) 
3. Periplasmic or outer membrane protein. 
These proteins are encoded by three different genes present in 
single operon. The cytoplasmic protein is otherwise termed as transporter 
protein. It is involved in the export of substrates such as antibiotics from 
the cell. MFP and OMP help in export mechanisms. Till date different 
classes of RND family efflux pumps have been reported in Acinetobacter 
species. Among them adeABC, adeFGH and adeIJK functions and 
specificities have been studied extensively. The overexpression of all 
these efflux pumps is controlled by two component regulatory systems 
such as sensor and regulator kinase cascade. 
 According to Magnet et al., adeABC  is one of the common 
types of efflux pumps. It invoved in posing resistance to antibiotics such 
as Aminoglycosides, Beta Lactams, Chloramphenicol, Tetracycline, 
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Trimethoprim, Erythromycin and drugs like Ethidium bromide62. 
 According to Chau et al., adeABC and adeDE  are species 
specific, whereas adeABC is restricted to Acinetobacter baumannii and 
adeDE to Acinetobacter genomespecies 363. In AdeABC pump  
AdeB – Multidrug transporter 
AdeA – Membrane fusion protein 
 AdeC – Outer membrane protein 
AdeB, the efflux transporter, captures the substrate within the 
phospholipid bilayer or the cytoplasm. The substrate is then transported 
out via OMP (AdeC). The AdeA acts as intermediate component, which 
overpass between AdeB and AdeC. AdeR-S two component system 
controls the expression of AdeB and AdeC components. 
 According to Marchand et al., point mutation in components of 
AdeABC and its regulatory proteins leads to overexpression of AdeABC, 
which in turn leads to multidrug resistance64.  
 
Penicillin binding protein 
 Carbapenem resistance in Acinetobacter baumannii is also due to 
penicillin binding protein (PBP) modifications. The penicillin binding 
domains of PBPs are transpeptidases or carboxypeptidases, that is 
involved in peptidoglycan metabolism. The expression of PBP is reduced 
in multidrug resistant strains in order to resist the activity of antibiotics. 
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Some of the strategies adopted by Acinetobacter baumannii are 
acquisition of an additional low affinity PBP, overexpression of an 
endogenous low affinity PBP and alterations in endogenous PBPs by 
point mutations or homologous recombination8. 
 
Resistance to aminoglycosides 
 Resistance to aminoglycosides by aminoglycoside modifying 
enzymes (AMEs) is a major threatening problem which leads to resistant 
phenotypes. All three classes of AMEs are found in Acinetobacter species. 
The enzymes are65 
1. O-nucleotidyltransferases – ANT(2”)-Ia, ANT(3”)-Id, ANT(3”)-Id 
encoded by aadB, aadA1, and aadA4 respectively. 
2. O-phosphotransferases – APH(3’)-Ia, APH(3’)-VIa, and 
APH(3’)-II encoded by aphA1, aphA6, and aphA15 respectively.  
3. N-acetyltranferase – AAC(3)-Ia, AAC(3)-IIa, AAC(6’)-Ib, 
AAC(6’)-Iad, AAC(6’)-Im and AAC(6’)-II encoded by aacC1, 
aacC2, aacA4, aac(6’)-Iad, aac(6’)-Im and aac(6’)-II respectively. 
O-nucleotidyltransferase and O-phosphotransferase catalyse the 
adenylation and phosphorylation of the hydroxyl groups. The 
N-acetyltransferases catalyse acetylation of amino groups thereby 




It has been reported that the occurrence of a combination of two or 
more of aminoglycoside modifying resistance genes and association of 
genes with class 1 integrons65.   
Recently, Acinetobacter baumannii strains producing the 16SrRNA 
methylase ArmA enzyme have been identified. ArmA is plasmid-encoded. 
It confers high level of pan aminoglyoside resistance comparing to the 
moderate level of resistance conferred by aminoglycoside modifying 
enzymes.This emerging resistance mechanism impairs aminoglycoside 
binding to target site and confers high level resistance to all clinically 
useful aminoglycosides like Amikacin, Gentamicin and Tobramycin66. 
AdeABC efflux pump less effectively transports Amikacin and 
Kanamycin due to their more hydrophilic nature. The MATE family 
efflux pump AbeM is reported in Acinetobacter which is responsible for 
exerting resistance to gentamicin and kanamycin4. 
 
Quinolone resistance 
 Quinolone resistance is caused by modifications in the structure of 
DNA gyrase secondary to mutations in the quinolone resistance 
determining regions (QRDR) of the gyrA and parC genes67. 
DNA gyrase and DNA topoisomerase IV encoded by gyrA and 
parC genes respectively are the housekeeping genes involved in DNA 
replication and processing. They are the targets for ciprofloxacin and 
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other fluoroquinones. A point mutation on the gyrA gene (Ser-83 to leu) 
was observed in MDR strains of Acinetobacter baumannii. It is 
responsible for fluoroquinolone resistant phenotype. 
According to Deccache et al., sequencing of the parC gene 
indicates mutations in the parC gene that caused an amino acid change at 
either Ser-80 or Glu-8468.  
Similar to aminoglycosides, quinolones resistance is also conferred 
by multidrug efflux pumps including the RND type pump AdeABC and 
the MATE pump AdeM. 
 
Resistance to Tetracyclin 
    Resistance to tetracycline and their derivatives are mediated by 
efflux or ribosomal protection. Tetracyclin efflux pump tet(A) and tet(B) 
are found in Acinetobacter. tet(A) is found within a transposon, in 
association with an IS element. Ribosomal protection is mediated by the 
tet(M) and tet(O)69. Apart from tetracycline specific efflux pump, it is 








Resistance to other antibiotics 
Trimethoprim-Sulfamethoxazole resistance in Acinetobacter 
baumannii is high in many geographical regions. Integrons are very 
common among strains of Acinetobacter that have a multidrug resistance 
phenotype. The 3’ conserved region of an integron contains a qac gene 
fused to a sul gene, confers resistance to antiseptics and sulfonamides70. 
Genes coding for Trimethoprim (dhfr) and Chloramphenicol (cat) 
resistance are also present within integron structures in Acinetobacter 
baumannii. Efflux pumps may also confers resistance against these 
agents71,72. 
 
Management, therapeutic options and susceptibility testing 
 Guidelines for minimum inhibitory concentration and disk 
diffusion interpretative criteria for suggested groups of antibiotics have 
been provided by the National committee for clinical Laboratory 
standards. Regardless, the clinical management of opportunistic and 
coinfections with the Acinetobacter is perhaps one of the biggest 
challenges clinicians facing today, particularly in medical, surgical, 
rehabilitation, and intensive care units. Resistance among clinical isolates 





 Clinical isolates are predictably resistant to Penicillin, Ampicillin, 
first generation Cephalosporins and Chloramphenicol, activity is variable 
against Carbenicillin, Tetracyclines, Aminoglycosides, second and third 
generation Cephalosporins, Quinolones, Trimethoprim-sulfamethoxazole 
and carbapenems2. 
Antimicrobial susceptibility testing for Acinetobacter species is 
problem prone. Swenson and colleagues at the CDC have shown that 
results obtained using standardized microbroth dilution do not agree with 
results obtained with the standardized disk diffusion method for certain 
antibiotics. Very major errors were frequent with the beta lactam and beta 
lactam inhibitor combination antibiotics with the microbroth dilution 
method typically showing greater resistance. At present, there are no data 
to indicate which method provides more clinically relevant information5. 
 Due to the unpredictable multiresistant patterns of nosocomial 
strains, consideration must be given to the prevalent susceptibility 
profiles within the institution. Strains of A. calcoaceticus-baumannii 
complex typically are more antimicrobial resistant than A. lwoffii, 
probably due to their higher prevalence within the hospital environment 








 If isolates retain susceptibility to Carbapenems class of 
antimicrobial agents, carbapenem remains the treatment of choice. The 
Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) 
surveillance program has documented that imipenem as the more potent 
agent for the treatment of multidrug resistant Acinetobacter infection, on 
comparing with meropenem. Unfortunately, carbapenem resistant 
Acinetobacter isolates are increasingly reported worldwide73,74. 
 
Beta lactamase inhibitors 
 Beta lactamase inhibitors, particulary sulbactam have intrinsic 
activity against Acinetobacter strains. For multidrug resistant 
Acinetobacter infections, several studies have demonstrated clinical 
efficacy of sulbactam in combination with ampicillin or cefoperazone75,76.  
 
Tigecycline 
 Tigecycline, a new glycylcycline agent, has bacteriostatic activity 
against multidrug resistant Acinetobacter77. Studies documented that 
overexpression of a multidrug efflux pumps in Acinetobacter isolates 




When adequate peak serum concentration is achieved, tigecycline is best 
reserved for salvage therapy78. 
 
Aminoglycosides  
 Many multidrug resistant Acinetobacter isolates retain 
intermediate susceptibility to amikacin or tobramycin. Resistance to this 
class of antimicrobial agents is increasingly associated with 
aminoglycoside modifying enzymes or efflux pump. These agents are 
used in combination with another active antimicrobial agent. 
 
Polymyxin 
 As limited therapeutic options are available, clinicians have 
returned to the use of polymyxin B or polymyxin E (colistin) for the 
multidrug resistant Acinetobacter infections79,80. Colistin acts by 
disturbing the bacterial cell membrane, which increases the permeability 
leading to cell death. Colistin is bactericidal against Acinetobacter. Its 
effect is concentration dependent. Resistance to polymxin is due to outer 
cell membrane alterations or efflux pump81. Studies have reported that 
cure or improvement rate for colistin is 57% to 77% among severely ill 





Synergy and combination therapy 
 Combined treatment with an aminoglycoside and Ticarcillin or 
Piperacillin is synergistic and may be effective in serious infections.  
According to Montero et al., the best regimen in a mouse 
pneumonia model is Colistin and Rifampin, Imipenem and Rifampin, 
Tobramycin and Rifampin, Imipenem and Tobramycin84. 
According to Yoon et al., synergy with double and triple 
combinations are obtained with Polymyxin B with Imipenem or 
Rifampin85. 
According to Tan et al. Colistin and Minocycline combination has 
synergical effect86. 
According to Kroeger et al., Ceftazidime prevents regrowth and 
development of Colistin resistance hence Colistin and continuously 
infused ceftazidime is advisable87. 
According to song et al., Colistin and Rifampin combination has 
synergy effect compared to Colistin alone88. 
Li et al found heteroresistance (subpopulation with varying level of 
resistance to Colistin) in Colistin susceptible Acinetobacter isolates 
studied in vitro89. 
Owen et al suggested that combination therapy is advisable to 





 1. Standard precautions includes hand hygiene, correct and 
consistent use of gloves, appropriate use of gowns and eye protection. 
 2. Contact barrier precautions includes dedicate patient care 
equipment and gowns and gloves for health care personnel on entry to an 
isolation room. 
   3. Environmental cleaning and disinfection. 
 4. Cohorting of health care personnel i.e designating staff to care 
for only patient colonized or infected with the organism. 
 5. Clinical unit closure is required in some outbreak settings to 
interrupt transmission and for thorough environmental disinfection. 
 6. Antimicrobial stewardship i.e programs to promote judicious 
antimicrobial use and prevent emergence of resistance. 
 7. Passive and active surveillance can be done to identify infected 



























MATERIALS AND METHODS 
 
Place of study    : Thanjavur Medical College and Hospital, Thanjavur. 
Period of Study : One year between June 2013 and May 2014 
Design of study  : Observational study 
Collabrating Departments: Medicine, Surgery, Paediatrics, Obstetrics 
&Gynaecology, Plastic surgery, ENT, Neurosurgery. 
Ethical clearance : Prior approval obtained from Ethical Committee 
Inclusion Criteria : 
1. Patients of all age group  
2. Patients of both gender 
3. Samples – urine, pus, blood, sputum 
4. Patients not taken prior antibiotic therapy. 
Exclusion Criteria : 
1. Samples – body fluids   
2. Patients taken prior antibiotic therapy 
Plan of study 
Eighty isolates of Acinetobacter were included in this study. These 
had been isolated from urine, pus, blood and sputum samples received in 






 Presumptive identification of Acinetobacter was made by inoculating 
the sample on Nutrient agar plate, MacConkey agar plate and Blood agar 
plate and incubated at 37○C for 24 hours. All non lactose fermentors were 
subjected to Gram staining, hanging drop and biochemical test like  
catalase, oxidase, indole, methyl red, voges proskauer, TSI, urease, citrate 
and nitrate reduction test. Acinetobacter are Gram negative bacilli or 
coccobacilli, non motile, oxidase negative, catalase positive, indole 
negative, methyl red negative, voges proskauer negative, non fermentor, 
citrate positive, urease variable. Acinetobacter was further confirmed by 
inoculation on selective media, Leeds Acinetobacter media. Speciation 
was done on the basis of glucose oxidation, hemolysis in blood agar, 
growth at 37○C and 42○C, Arginine decarboxylation test, 1% and 10% 
lactose and susceptibility to chloramphenicol. Antimicrobial 
susceptibility testing was done by Kirby bauer disc diffusion method for 
Ampicillin, Gentamicin, Amikacin, Cephalexin, Ceftriaxone, 
Ciprofloxacin, Cotrimoxazole, Chloramphenicol and Imipenem. 
Molecular characterization of Acinetobacter for blaOXA-51 gene was done 







Samples received were inoculated on Nutrient agar plate, Macconkey 
agar plate and Blood agar plate, and incubated at 37○C for 24 hours. 
Nutrient agar plate – 1-2 mm non pigmented, domed colonies with 
smooth surfaces. 
MacConkey agar plate – Non lactose fermentors, but colonies exihibit a 
faint pink tint.  




 In gram positive bacteria, the purple crystal violet/iodine complex is 
retained within the cell after washing with acetone because the thick 
peptidoglycan layer does not allow the crystal violet iodine complex to be 
washed out of the cell. In gram negative bacteria, the crystal violet/iodine 
complex is leached from the cell because of disruption of the lipid-rich 
outer membrane by the acetone. 
Procedure: 
1. Cover the smear with crystal violet for 1 min. 
2. Rinse gently under tap water. 
3. Cover the smear with Gram’s iodine for 1 min. 
















































5. Decolourise with acetone. 
6. Immediately rinse under tap water. 
7. Counterstain with dilute carbol fuchsin for 1 minute. 
8. Rinse the smear under tap water and air dry it. 
Observe the smear first under low power and then under oil 
immersion. 
Quality control: 
Staphylococcus aureus – Purple coloured Gram positive bacteria. 
Escherichia coli – Pink coloured Gram negative bacteria 
Observation: 
Presence of pink coloured coccobacilli 
Interpretation: 
Gram negative bacilli or coccobacilli  
 
Hanging – drop procedure: 
 The technique is generally used for studying the motility of the 
bacteria. 
Procedure: 
1. Take a clean grease free cavity slide 
2. Take a clean coverslip, apply paraffin to four corners of coverslip. 
3. Place a drop of colony emulsified in normal saline on the coverslip 
with the help of inoculating loop. 
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4. Place the cavity slide over the coverslip so that the drop is placed in 
the centre. 
5. Invert the slide, and observe under microscope 
6. First observe under low power, locate the edge of the drop, shift the 
focus to high power and observe for motility of the organism. 
Observation: 
 The bacteria showed no motility. 
Interpretation: 
 The organism is non motile. 
 
Biochemical Reaction:  
 
Cytochrome Oxidase Test: 
Principle:  
 The cytochromes are iron containing hemoproteins that act as the last 
link in the chain of aerobic respiration by transferring electrons to oxygen, 
with the formation of water. The cytochrome system is found in aerobic, 
microaerophilic, and facultative anaerobic organisms, so the oxidase test 
is important in identifying organisms that either lack the enzyme or are 
obligate organisms. 
 
 The cytochrome oxidase test uses certain reagent dye, such as Tetra 
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methyl para phenylenediamine dihydrochloride, that substitutes for 
oxygen as artificial electron acceptors. In the reduced state, the dye is 
colourless, however in the presence of cytochrome oxidase and 
atmospheric oxygen, para phenylenediamine is oxidized , forming 
indophenols and appears blue. 
Procedure: 
 The indirect paper strip procedure, in which a few drops of the 
reagent are added to a filter paper strip. The tetramethyl derivative of para 
phenylenediamine is used because it is more stable in storage and more 
sensitive to the detection of cytochrome oxidase and is less toxic than the 
dimethyl derivative. A loopful of colony is smeared into the reagent zone 
of paper. 
Quality Control: 
 Positive control – Pseudomonas aeruginosa 
 Negative control – Escherichia coli 
Observation: 
 The colour of the smear in the zone of the filter paper remains 
unchanged 
Interpretation: 







 Catalase is an enzyme that decomposes hydrogen peroxide into water 
and oxygen. Chemically catalase is a hemoprotein, similar in structure to 
hemoglobin, except that four iron atoms in the molecule are in the 
oxidized, rather than the reduced state. 
Hydrogen peroxide forms as one of the oxidative end products of 
aerobic carbohydrate metabolism. If allowed to accumulate, it is lethal to 
bacterial cells. Catalase converts hydrogen peroxide into oxygen and 
water. 
Procedure: 
 Take 1 ml of 3% hydrogen peroxide in test tube. Introduce small 
quantity of bacterial growth into the fluid with the help of a glass rod or 
plastic loop and touch the side of the tube. Observe for the release of 
bubbles. 
Quality Control: 
 Positive control – Staphylococcus aureus  
 Negative control – Streptococcus species. 
Observation:  
 The rapid and sustained appearance of bubbles formed. 
Interpretation: 
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    Indole, a benzyl pyrrole, is one of the metabolic degradation 
products of the amino acid tryptophan. Bacteria that possess the enzyme 
tryptophanase are capable of hydrolyzing and deaminating tryptophan 
with the production of indole, pyruvic acid, and ammonia.The indole test 
is based on the formation of a red complex when indole reacts with the 
aldehyde group of p-dimethylaminobenzaldehyde. This is the active 
chemical in Kovac and Ehrlich reagent. 
Procedure: 
 Inoculate peptone water with colonies of Acinetobacter and 
incubate at 35○C for 18 to 24 hours. At the end of this time, add drop of 
kovac’s reagent down the inner wall of the tube. 
Quality control: 
 Positive control – Escherichia coli 
 Negative control – Klebsiella pneumonia 
Observation: 
 Development of yellowish green colour ring at the interface of the 
reagent and broth within few seconds after adding kovac’s reagent  
Interpretation: 




Methyl Red Test5: 
Principle: 
 Methyl red is a pH indicator with a range between 6.0 (yellow) and 
4.4 (red). The pH at which methyl red detects acid is considerably lower 
than the pH for other indicators used in bacteriologic culture media. 
Hence for producing a color change, the test organism must produce large 
quantities of acid from the carbohydrate substrate used. 
 The methyl red test is a quantitative test for acid production, requiring 
positive organisms to produce strong acids (lactic, acetic, formic) from 
glucose through the mixed acid fermentation pathway. 
Procedure:  
 1. Inoculate the MR broth with a pure culture of the test organism. 
Incubate the broth at 35○C for 48 to 72 hours. 
 2. At the end of this time, add 5 drops of the methyl red reagent 
directly to the broth. 
Quality control: 
 Positive control – Escherichia coli 
 Negative control – Enterobacter aerogenes 
Observation:  
 Yellow colour developed 
Interpretation: 
 Yellow color indicates the organism was methyl red negative. 
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Voges Proskauer Test: 
Principle: 
Pyruvic acid, the pivotal compound formed in the fermentative 
degradation of glucose, is further metabolized through various metabolic 
pathways, depending on the enzyme systems possessed by different 
bacteria. One such pathway results in the production of acetoin (acetyl 
methyl carbinol), a neutral reacting end product. In the presence of 
atmospheric oxygen and 40% potassium hydroxide, acetoin is converted 
to diacetyl and alpha naphthol serves as a catalyst to bring out a red 
complex. 
Procedure:  
 Inoculate a tube of VP broth with a pure culture of the test 
organism. Incubate for 24 hours at 35○C. At the end of this time, 1 ml of 
broth is taken in a clean test tube. Add 0.6 ml of 5% alpha napthol, 
followed by 0.2 ml of 40% KOH. Shake the tube gently to expose the 
medium to atmospheric oxygen and allow the tube to remain undisturbed 
for 10 to 15 minutes. 
Quality control:  
 Positive control – Enterobacter aerogenes 
 Negative control – Escherichia coli 
Observation: 




VP test was negative for this organism. 
 
Citrate Utilisation Test: 
Principle: 
 Sodium citrate is a salt of citric acid, a simple organic compound 
found as one of the metabolites in the tricarboxylic acid cycle (Krebs 
cycle). Some bacteria obtain energy in a manner other than by the 
fermentation of carbohydrates by using citrate as the sole source of 
carbon. The utilization of citrate by the test bacterium is detected in 
citrate medium by the production of alkaline by products. The medium 
includes sodium citrate, an anion, as the sole source of carbon, and 
ammonium phosphate as the sole source of   nitrogen. Bacteria that can 
use citrate can also extract nitrogen from the ammonium salt, with the 
production of ammonia, leading to alkalinization of the medium from the 
conversion of the ammonia to ammonium hydroxide. Bromothymol blue- 
yellow below pH 6.0 and blue above pH 7.6 is the indicator. 
Procedure: 
 A well isolated colony is picked up and inoculated as single streak on 
the slant surface of the simmon’s citrate agar tube. The tube is incubated 





 Positive control – Enterobacter aerogenes 
Negative control – Escherichia coli 
Observation: 
Change of medium into deep blue colour.  
Interpretation: 
 Change of medium into deep blue colour indicates the organism has 
been able to utilize the citrate contained in the medium, with the 




 Urea is a diamide of carbonic acid. All amides are easily 
hydrolyzed with the release of ammonia and carbon dioxide. Urease is an 
enzyme possessed by many species of microorganism that can hydrolyze 
urea. The ammonia reacts in solution to form ammonium carbonate, 
resulting in alkalinization and increase in the pH of the medium. 
Procedure:   
 Christensen’s urea agar slope is inoculated with colonies of 






        Citrate utilization test          Urease test      
         





                 TSI test               Nitrate reduction test 
                                                       
               










 Positive control – Proteus mirabilis  
   Negative control – Escherichia Coli 
Observation: 
No colour change in the medium  
Interpretation: 
 No colour change in the medium. So the enzyme urease is not 
produced by the organism.  
 
Triple Sugar Iron Agar Test (TSI): 
Principle: 
 The TSI agar is distributed in the tube which contains a slant and 
a butt. TSI medium indicates whether the bacteria ferments glucose only, 
or lactose and sucrose also with or without production of gas. The 
medium can detect production of hydrogen sulphide as well as other 
bacteria which utilizes only glucose. Due to the acid production , the 
colour of the indicator (phenol red) is changed to yellow and the whole 
medium appears yellow in colour. After further incubation as the glucose 
is fully exhausted, the bacteria begin to oxidatively degrade the amino 
acid present in the medium. Since oxygen is exposed only to the slant 
portion, oxidative degradation occurs only in the slant portion.This 
oxidative degradation results in the production of alkali products, which 
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reverts the colour of the slant to red colour. In the deeper part of the tube, 
amino acid degradation is insufficient to overcome the acid formed, so 
medium in the butt part remains yellow in colour. 
 If the TSI medium is inoculated with lactose fermenting organism, 
then even after the glucose is completely used up in first 8-12 hours, 
fermentation continues as the organism is abe to use lactose which is 
present in concentration 10 times that of glucose. So the acid production 
continues to occur even after 18-24 hours and both the slant and butt 
appear yellow. 
 For the detection of H2S which is a colourless gas, medium must 
include an indicator to detect the H2S. Sodium thiosulphate is the source 
of sulfur atoms. Ferrous sulfate is the indicator used for the detection of 
the H2S which is indicated by the production of insoluble black 
precipitate. 
Procedure: 
 Inoculate the colony into the tube by means of stab and streak 
inoculation and incubate for 18-24 hours at 37○ C. 
Quality Control: 
 Alkaline slant / alkaline butt – Pseudomonas aeruginosa 
Observation:  
 Alkaline slant / No change (K/ No change) no H2S production, shows 




 The bacteria is non fermentor 
Nitrate reduction Test : 
Principle: 
 Organisms demonstrating nitrate reduction have the capability of 
extracting oxygen from nitrates to form nitrites and other reduction 
products. The presence of nitrites in the test medium is detected by the 
addition of alpha naphthylamine and sulfanilic acid, with the formation of 
a red diazonium dye, p-sulfobenzeneazo- alpha naphthylamine. 
Procedure: 
 Inoculate the nitrate medium with a loopful of test organism and 
incubate at 35○C for 18 to 24 hours. 
 At the end of incubation, add 1ml of 0.5% alpha naphthol and 
sulfanilic acid. 
Quality control:  
 Positive control – Escherichia coli  
 Negative control – Acinetobacter baumannii 
Observation:  
 No color develops. 
Interpretation:  




Culture on selective media: 
Leeds Acinetobacter Medium(HI MEDIA) 
 Recommended for the isolation of Acinetobacter species. 
Principle: 
 Casein acid hydrolysate and soya peptone provides nitrogenous 
compound and vitamins to the organism. Sucrose, fructose and mannitol 
provides carbohydrate source. Sodium chloride provides osmotic balance. 
Phenol red serves as pH indicator. The liberation of ammonia ions by the 
utilization of nitrogenous material in the medium results in pink colour. 
Procedure: 
 Inoculate the organism on Leeds Acinetobacter medium and 
incubate at 37○ C for 18 to 24 hours. 
Quality control: 
Appearance 
 Light yellow to pink coloured homogenous free flowing powder 
Gelling 
 Firm, comparable with 1.2% agar gel 
Colour and clarity of prepared medium 
 Red colour clears to slightly opalescent gel forms in petri plate 
Reaction 




Leeds Acinetobacter medium 















 Pink mucoid colonies with pink colour diffuses into the medium. 
Interpretation: 
 The organism is Acinetobacter. 
 
Oxidative – Fermentative Test (Hugh and Leifson): 
Principle: 
 Saccharolytic microorganisms degrade glucose either 
fermentatively or oxidatively. The end products of fermentation are 
relatively strong mixed acids that can be detected in a conventional 
fermentation test medium. However, the acid formed in oxidative 
degradation of glucose are extremely weak, and the more sensitive 
oxidation-fermentation medium of Hugh and Leifson is required for the 
detection. 
 The OF medium of Hugh and Leifson differs from carbohydrate 
fermentation media-   
      1. Peptone decreased from 1% to 0.2% 
   2. Carbohydrate is increased from 0.5% to 1.0% 
    3. Agar is decreased from 1.5% to 0.3%, making it semisolid. 
The lower protein/carbohydrate ratio reduces the formation of 
alkaline amines that can neutralize the small quantities of weak acids that 
may form from oxidative metabolism. The relatively larger amount of 
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carbohydrate serves to increase the amount of acid that can potentially be 
formed. The semisolid consistency of the agar permits acids that forms on 
the surface of the agar to permeate throughout the medium, making 
interpretation of the pH shift of the indicator easier to visualize. 
Procedure: 
 Two tubes of OF medium are required. Inoculate the colonies of 
Acinetobacter into both tubes. One tube is covered with 1 cm layer of 
melted paraffin, leaving the other tube open to the air. Incubate both tubes 
at 35○C and examine daily for several days. 
Quality control: 
 Glucose fermenter – Escherichia coli 
 Glucose oxidizer – Pseudomonas aeruginosa 
 Nonsaccharolytic – Moraxella species 
Observation: 
  Open tube   Covered tube   Metabolism  
  Yellow       Green     Oxidative 
  Green    Green     Nonsaccharolytic 
Interpretation: 
 Oxidative – Acinetobacter baumannii 





Arginine Decarboxylase Test: 
Principle: 
Decarboxylase are a group of substrate specific enzyme that are 
capable of reacting with the carboxyl portion of amino acids, forming 
alkaline reacting amines. This reaction, known as decarboxylation, forms 
carbondioxide as a second product. Decarboxylase enzyme is specific for 
arginine. 
 The conversion of arginine to citrulline is a dihydrolase, rather 
than a decarboxylase reaction, in which an NH2 group is from arginine as 
a first step. Citrulline is next converted to ornithine, which then 
undergoes decarboxylation to form putrescine. 
 Moeller decarboxylase medium is the base most commonly used 
for determining the decarboxylase capabilities. The amino acid, arginine 
is added to the decarboxylase base before inoculation with the 
organism.The tubes are anaerobically incubated by overlying with 
mineral oil. During initial stages of incubation the tube turns yellow, 
owing to the fermentation of the small amount of glucose in the medium. 
If arginine is decarboxylated, alkaline amines are formed and the medium 







                     
                   OF test - Oxidative 
 
                  PC          TEST      NC 
      
 
 Arginine – positive         1% & 10% lactose-acid production    
               






Acinetobacter lwoffii  
               OF test – Non saccharolytic 
 
        PC             TEST        NC             
 
    Arginine - negative          1% & 10% lactose   
                                 No acid production 
                                             





 A well isolated colony of Acinetobacter is inoculated into the 
medium and overlay with sterile mineral oil to cover about 1 cm of the 
surface and incubate at 35○C for 18 to 24 hours. 
Quality control: 
 Positive control – Enterobacter cloacae 
 Negative control – Enterobacter aerogenes 
Observation: 
 Conversion of the tube to yellow.  
 Conversion of the tube to yellow and reversion of the tube to purple 
colour. 
Interpretation:  
 Yellow – Acinetobacter lwoffii  
 Yellow to purple – Acinetobacter spp other than Acinetobacter lwoffi 
 
Antimicrobial sensitivity testing  
Storage of antimicrobial discs 9,94 
 The antimicrobial disc container was stored at 4 - 8° C while 
the β-lactam antibiotics were stored in the freezer compartment. Some 
labile agents like Imipenem retained greater stability when stored frozen 




Disc container was taken out from refrigerator one or two hours 
before use and brought to room temperature. Once a cartridge of discs has 
been removed from its sealed package, after the use it was replaced in a 
tightly sealed dry container. 
 
Preparation of turbidity standard 9,94  
  McFarland standards prepared by adding specific volumes of 
1% Suphuric acid and 1.175 % barium chloride to obtain a barium sulphate 
solution with a specific optical density. The most commonly used is the 
McFarland 0.5 standard, which contains 99.5ml of 1% sulphuric acid and 
0.5 ml of 1.175 % barium chloride. This solution is distributed in tubes and 
compared to those used for inoculum preparation, which are sealed tightly 
and stored in the dark at Room temp. The McFarland 0.5 standard provides 
a turbidity comparable to that of a bacterial suspension containing 
approximately 1.5 X 10 8 CFU/ml. 
 
Preparation of Inoculum9,94 
 In order to prepare the inoculum, about 3-5 representative colonies 
were picked up and inoculated in 4-5 ml of peptone water and incubated at 
37°C for 2 – 6 hrs to attain 0.5 McFarland’s standard which corresponds to 
150 million organisms/ml. If it was more turbid, then some more quantity 
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of peptone water was added and adjusted to 0.5 McFarland’s standard by 
comparing against a card with white background and contrasting black 
lines. 
 
Inoculation of MHA plates 
Within 15 minutes of adjusting the turbidity of the inoculum 
suspension, dispense the suspension on surface of medium and close the lid. 
Holding the plate with both the hands, make suspension flow uniformly 
over entire surface of medium by slowly rotating the plate. Drain out 
excess fluid and wipe the rim of plate with cotton dipped in Lysol. The 
plate was closed and left for 3-5 minutes to allow any excess surface 
moisture to be absorbed before applying drug impregnated discs. 
   
Application of discs to inoculated agar plate: 
    The predetermined battery of antimicrobial discs of Ampicillin, 
Gentamicin, Amikacin, Cephalexin, Ceftriaxone, Ciprofloxacin, 
Cotrimaxazole, Chloramphenicol, Imipenem were tested for all the isolates.  
   The entire disc were placed on agar plates and pressed down to 
ensure complete contact with the agar surface. Discs were distributed 
evenly so that they were not closer than 25 mm from centre to centre of the 





Reading and interpretation of results 
  After 16-18 hrs of incubation, each plate was examined for 
satisfactory streaking showing confluent lawn of growth with uniformly 
circular zones of inhibition around the drug disc.   
The diameter of the zones of complete inhibition including the 
diameter of the discs was measured. The zones were measured to the 
nearest millimetre using a ruler that was held on the back by inverting Petri 
plate. The Petri plate was held a few inches above a black, non reflecting 
background and illuminated with reflected light. The zone margin showing 
no obvious visible growth that could be detected with unaided eyes was 
considered as a zone of inhibition. The sizes of the zones of inhibition were 
interpreted by referring to the CLSI standards and reported as ‘susceptible’, 




Antimicrobial susceptibility testing 
     Sensitive pattern                Sensitive pattern 
            
 











Resistant pattern                  II line drug 


























1. Gentamicin GEN 10 < 12 13-14 > 15 
2. Amikacin AK 30 <14 15-16 >17 
B. Penicillin 
1. Ampicillin AMP 10 <13 14-16 >17 
C. Sulphonamides 
1. Cotrimoxazole COT 1.25/23.75 <10 11-15 >16 
D. Quinolones 
1. Norfloxacin NX 10 <12 13-16 >17 
2. Ciprofloxacin CIP 5 <15 16-20 >21 
E. Cephalosporins 
1. Cephalexin CN 30 <14 15-17 >18 
2. Ceftriaxone CTR 30 <13 14-20 >21 
F. Carbapenems 
1. Imipenem IMP 10 <13 14-15 >16 
G. Macrolides      
1. Chloramphenicol C 30 <12 13 – 17 18 
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II line drugs      
1. Doxycycline DO 30 12 13 - 15 16 




PIT 100/10 17 18 - 20 21 
4. Polymyxin-B PB 300 11  12 
5. Colistin CO 10 10  11 
 
MOLECULAR CHARACTERIZATION OF ACINETOBACTER 
Conventional Polymerase Chain Reaction was done for 14 isolates 
for the detection of blaOXA-51 gene. Isolates were selected randomly based 
on the following features. 
1. PCR was done for twelve Acinetobacter baumannii strains. out 
of which four isolates were resistant to Imipenem. Remaining eight 
isolates were sensitive to Imipenem. 
2. PCR was also done for two Acinetobacter lwoffi strains. 
Gene Identification   
Material & Methods:  
DNA purification kit (PureFast® Bacterial Genomic DNA 
purification kit), PCR Master Mix, Agarose gel electrophoresis 
consumables and Primers are from HELINI Biomolecules, Chennai, 
India.     
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2X Master Mix :   
It contains 2U of Taq DNA polymerase, 10X Taq reaction buffer, 
2mM MgCl2, 1µl of 10mM dNTPs mix and PCR additives.   
Agarose gel electrophoresis:  
Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium 
bromide are from HELINI Biomolecules, Chennai.    
OXA-51 gene primer   
Forward Primer: 5'-CTTGCTCGTGCTTCGACCGAGT-3  
Reverse Primer: 5'-CGCCTAGGGTCATGTCCTTTTCCC-3'   
PCR Product size: 160bp 
 
Procedure 
1. Pellet is suspended in 200µl of PBS.   
2. Added 50µl of Lysozyme and incubated at 37ºC for 15min.   
3. 400µl of Lysis buffer and 40µl of Proteinase K [10mg/ml] is 
added and gently mixed well.   
4. Incubated in water bath at 56°C for 10 min.  
5. Add 200µl of Isopropanol and mix well.   
6.Transferred whole lysate into PureFast spin column and 
centrifuged at 10000rpm for 1min.    
7. Discard flow through and added 500µl of Wash Buffer and 
Centrifuge at 12000rpm 1 min.    
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8. Discard flow through and added 500µl of Wash Buffer-2 and 
centrifuged at 12000rpm for 1min. Repeated wash one more 
time.    
9. Discarded flow through and Centrifuged column for additional 
2 minute to remove any residual ethanol.   
10. Eluted DNA by adding 100µl of Elution Buffer and 
Centrifuged for 1min.   
11. Quality and Quantity of extracted DNA is checked by loading 




 [25µl of Master Mix contains: 10X Taq buffer, 2mM Mgcl2, 
0.4mM dNTPs mix, and 2U Proofreading Taq DNA polymerase]   
1. Reactions set up as follows;   
COMPONENTS IN PCR VIAL QUANTITY 




Genomic DNA 5µl 




2. Mixed gently and spin down briefly.   
3. Place into PCR machine and program it as follows;   
Initial Denaturation : 94ºC for 3 min   
Denaturation : 94ºC for 1 min 
 Annealing :    58ºC for 1min          35 cycles 
 Extension :    72ºC for 1min   
Final extension : 72º C for 5 min    
Loading: 
 1. Prepare 2% agarose gel. [2gm of agarose in 100ml of 1x TAE 
buffer]   
2. Mix 8µl 6X Gel loading dye to each PCR vial and loaded entire 
PCR product. 
3. Run electrophoresis at 50V till the dye reaches three fourth 
distances and observe the bands in UV Transilluminator. 
 
Agarose gel electrophoresis:   
1. Prepared 2% agarose. (2gm agarose in 100ml of 1X TAE buffer 
and melted using micro oven)   
2. When the agarose gel temperature was around 60ºC, added 5µl 
of Ethidium bromide.   
     3. Poured warm agarose solution slowly into the gel platform.     















  4. Kept the gel set undisturbed till the agarose solidifies. 
  5. Poured 1XTAE buffer into submarine gel tank.   
6. Carefully placed the gel platform into tank. Maintain the tank 
buffer level 0.5cm above than the gel.   
7. PCR Samples are loaded after mixed with gel loading dye along 
with 10µl HELINI 100bp DNA Ladder. [100bp, 200bp, 300bp, 
400bp, 500bp, 600bp, 700bp, 800bp, 900bp, 1000bp, 1500bp]   
8. Run electrophoresis at 50V till the dye reaches three fourth 
distance of the gel.   




 Band formation between 100bp and 200bp was formed for all the 
isolates except for 5th and 12th isolate.  
Interpretation: 
 BlaOXA-51 gene was detected in all the 12 Acinetobacter baumannii 







              Gel Electrophoresis 
      1 DNA Ladder   2     3    4     5     6   7         
 
 P         P     P     P    N     P     P 
             Band formation between 100 and 200 bp 
 
     8    9  DNA Ladder 10    11   12    13   14 
 
 P    P          P      P     N     P     P 
         





Nutrient agar plate: Circular, 1-2 mm, low convex, regular margin, 
smooth surface entire edge, colourless colonies, no odour.  
Mac Conkey agar plate : Circular, low convex, regular margin, smooth 
surface, entire edge, non lactose fermenting colonies with a faint pink tint 
and no odour.  
Blood agar plate : Circular, low covex, regular margin, smooth surface, 
entire edge, non hemolytic grey moist colonies and no odour. 
Gram Staining: 
 Gram negative coccobacilli  
Hanging drop: 
 Non motile 
Biochemical Reaction: 
  Catalase – Positive 
  Oxidase – Negative 
  Indole not produced 
  Methyl red - Negative  
  Voges proskauer – Negative 
  Citrate not utilised 
  Urease not produced 
  Triple sugar iron agar – Alkaline/ no change (K/NC) 
  Nitrates not reduced to nitrites 
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Leeds Acinetobacter Medium: 
 Pink mucoid colonies with pink colour diffuses into the medium. 
















+ + - O + A A R 
Acinetobacter 
lwoffii 
+ - - NS - - - S 
O – Oxidative, NS – Non Saccharolytic, A – Acid production, R- 
Resistant, S – Sensitive. 
 
Antimicrobial Susceptibility test: 
 The predetermined battery of antimicrobial discs of Ampicillin, 
Gentamicin, Amikacin, Cephalexin, Ceftriaxone, Ciprofloxacin, 
Cotrimoxazole, Imipenem and Chloramphenicol were tested for all the 
eighty isolates. Isolates which were resistant for all the above said drugs, 
were then tested for Doxycycline, Pipercillin, Piperacillin Tazobactum, 







Conventional Polymerase Chain Reaction was done for 14 isolates 
for the detection of blaOXA-51 gene. Isolates were selected randomly based 
on the following features. 
1. PCR was done for twelve Acinetobacter baumannii strains. out 
of which four isolates were resistant to Imipenem and remaining eight 
isolates were sensitive to Imipenem. 
2. PCR was also done for two Acinetobacter lwoffi strains. 
Out of the fourteen isolates, blaOXA-51 was detected in twelve 
Acinetobacter baumannii strains of both Imipenem sensitive and resistant. 


























Identification, speciation, antibiogram and molecular 
characterization of Acinetobacter isolated from the various clinical 
samples received in 24 hours Microbiology laboratory, Thanjavur 
Medical College and Hospital during the period of June 2013 to May 
2014. Eighty Acinetobacter strains were isolated from the urine, blood, 
pus and sputum samples.The eighty Acinetobacter strains were analysed 
for the distribution among sample wise, age wise, sex wise, ward wise, 
diagnosis wise etc. 
      
TABLE : 5 
TOTAL ISOLATES 
        






URINE 3444 1170 26 
BLOOD 2626 1181 22 
PUS 2889 1895 21 
SPUTUM 703 397 11 




Among the 9662 samples received, 4643 were culture positive .Out 
of the 4643 culture positive samples, 80 samples were found to be 
Acinetobacter.  
                 TABLE : 6 
PREVALENCE OF ACINETOBACTER 
      
In the present study, Acinetobacter isolates accounted for 1.7% of 
the total number of organisms isolated from urine, blood, pus and sputum 
during the study period of June 2013 to May 2014. 
TABLE : 7 
SPECIMEN WISE SCREENING 
                     
 
 TOTAL NO = 
4643 
PERCENTAGE 
ACINETOBACTER 80 1.7% 
SPECIMEN TOTAL NO = 80 PERCENTAGE 
URINE 26 32 
BLOOD 22 28 
PUS 21 26% 
SPUTUM 11 14% 
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Among the 80 isolates of Acinetobacter, 32.5% was isolated from 
urine, 27.5% was isolated from blood, 26% was isolated from pus and 
11% was isolated from sputum. 
  
TABLE : 8 
AGE WISE SCREENING 
           
 
Age wise screening: 
Among the 80 isolates of Acinetobacter, age group of 45 years and 
above (44%) was most commonly affected, followed by paediatric age 
group (30%), and then age group of 13-45 years (26%). 
AGE in years TOTAL NO = 80 PERCENTAGE 
0 – 12 24 30% 
13 – 45 21 26% 













    
 












TABLE - 9 
SEX WISE SCREENING 
      
SEX TOTAL NO =80 PERCENTAGE 
MALE 46 57.5% 
FEMALE 34 42.5% 
      
Sex wise screening: 
On further analysis of sex wise screening among 80 isolates of 
Acinetobacter, males (57.5%) were more commonly affected than 
females (42.5%) 
     TABLE : 10 
 OUT & IN PATIENT WISE SCREENING  
 TOTAL NO =80 PERCENTAGE 
IN PATIENT 72 90% 
OUT PATIENT 8 10% 
 
In patient & Out patient wise screening: 
 Among the 80 isolates Acinetobacter, infection was predominant 
in In-patients (90%) than out patient (10%). 
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TABLE : 11 
      WARD WISE SCREENING 
      
WARD TOTAL NO = 80 PERCENTAGE 
ICU 26 32.5% 
SURGERY 21 26.5% 




 OTHERS 8 10% 
 
Ward wise screening: 
    In the present study Acinetobacter was isolated more commonly 
from ICU (32.5%), followed by surgical wards (26.5%), medical wards 
(21%), obstetrics & gynaecology (10%) and others (10%).All the 
paediatric cases were from SNN and PICU. So included all the paediatric 








TABLE : 12 
DIAGNOSIS WISE SCREENING 
 
DIAGNOSIS TOTAL NO =80 PERCENTAGE 
UTI 25 31.5% 




PNEUMONIA 14 17.5% 
 
Diagnosis wise screening: 
Out of the 80 isolates of Acinetobacter, 31.5% of the patients were 
affected by UTI, then septicemia (26%), wound infection (25%) and 
pneumonia (17.5%). 
                     TABLE : 13 
DIFFERENT SPECIES OF ACINETOBACTER   
   


























In the present study most of the strains were Acinetobacter baumannii 
(77.5%) and then Acinetobacter lwoffii (22.5%). 
TABLE : 14 
SENSITIVITY PATTERN OF ACINETOBACTER TO IMIPENEM 
            
IMIPENEM TOTAL NO =80 PERCENTAGE 
SENSITIVE 73 92% 
RESISTANT 7 8% 
 
In the present study strains resistant to imipenem was 8% and 



















TABLE : 15 




SENSITIVE INTER MEDIATE RESISTANT 
n =80 Per 
centage n = 80 
Per 
centage n =80 
Per 
centage 
AMPICILLIN 6 8% 9 11% 65 81% 
GENTAMICIN 43 54% 8 10% 29 36% 
AMIKACIN 57 71% Nil Nil 23 29% 
CEPHALEXIN 6 8% 5 6% 69 86% 
CEFTRIAXONE 33 41% 12 15% 35 44% 
CIPROFLOXACIN 32 40% 9 11% 39 49% 
COTRIMOXAZOLE 17 21% 17 21% 46 58% 
CHLORAM 
PHENICOL 17 21% 10 13% 53 66% 
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  Acinetobacter strains were resistant to Ampicillin (81%), 
Gentamicin (36%), Amikacin (29%), Cephalexin (86%), Ceftriaxone 
(44%), Ciprofloxacin (49%), Cotrimoxazole (58%), Chloramphenicol 
(66%) 
The isolates which were resistant to all the above drugs were tested 
for the II line drugs, Doxycycline, Piperacillin, Piperacillin Tazobactum 
and Polymyxin. Isolates resistant to Imipenem were sensitive to 
Polymyxin and Colistin. 
 
Molecular characterisation of Acinetobacter 
 Conventional PCR for detection of blaOXA-51 gene was done for 8 
Acinetobacter baumannii strains sensitive to Imipenem, 4 Acinetobacter 
baumannii strains resistant to Imipenem, and 2 Acinetobacter lwoffii 
strains. Out of which 12 Acinetobacter baumannii strains (both Imipenem 
sensitive and resistant) were positive for blaOXA-51 gene and 2 





 Acinetobacter isolates accounted for 1.7% of total number of 
organisms isolated during the study period. 
 Isolation rate was more from urine samples. 
 Age group of 45years & above were more commonly affected. 
 Males were more commonly affected than females. 
 Acinetobacter infection was more common in In-patients than out 
patients. 
 Most of the isolates were from Intensive Care Units (ICU). 
 Most of the patients had urinary tract infection. 
 Acinetobacter baumannnii was the predominant species isolated 
among the 80 Acinetobacter strains. 
 Imipenem resistance was seen among 8% of the isolates. Isolates 
resistant to Imipenem were sensitive to Colistin and Polymyxin. 
 Acinetobacter strains were resistant to Ampicillin (81%), Gentamicin 
(36%), Amikacin (29%), Cephalexin (86%), Ceftriaxone (44%), 
Ciprofloxacin (49%), Cotrimoxazole (58%), Chloramphenicol (66%) 
 Conventional PCR was done for 14 isolates of Acinetobacter for the 
detection of blaOXA-51. It showed positive result in all the 12 
Acinetobacter baumannii strains (both Imipenem sensitive and 





















Eighty isolates of Acinetobacter were included in the present 
study.They had been isolated from urine, blood, pus and sputum samples. 
Presumptive identification of Acinetobacter was made by inoculation of 
the sample on MacConkey agar medium, Nutrient agar medium and 
Blood agar medium and incubated at 37○C for 24 hours. All non lactose 
fermentors were subjected to Gram staining, hanging drop and 
biochemical test like oxidase, catalase, indole, methyl red, voges 
proskauer, TSI, urease, citrate and nitrate reduction test. Acinetobacter 
was further confirmed by inoculation on selective media, Leeds 
Acinetobacter media. Speciation was done on the basis of glucose 
oxidation, hemolysis on blood agar, growth at 37○C and  42○C, Arginine 
decarboxylation test, 1%  lactose and 10% lactose and susceptibility to 
chloramphenicol. Antimicrobial susceptibility testing was done by Kirby 
bauer disc diffusion method. Molecular characterization of Acinetobacter 
for blaOXA-51 gene was done by conventional PCR for fourteen isolates. 
 All the eighty isolates of Acinetobacter showed growth in the 
selective media, Leed’s Acinetobacter media. On speciation two species 
of Acinetobacter were detected. The predominant species was 
Acinetobacter baumannii (77.5%) and next to it is Acinetobacter lwoffi 
(22.5%). Seven Imipenem resistant Acinetobacter baumannii species 
were detected. But all the Acinetobacter lwoffii were sensitive to 
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imipenem. Conventional PCR was done for 14 samples (8 Imipenem 
sensitive Acinetobacter baumannii, 4 Imipenem resistant Acinetobacter 
baumannii and 2 Acinetobacter lwoffii) for the detection blaOXA-51 
gene.BlaOXA-51 gene was detected in Acinetobacter baumannii of both 
imipenem sensitive and resistant strains. The gene was not detected in the 
Acinetobacter lwoffii strains. 
 
Prevalence of acinetobacter: 
In the present study Acinetobacter isolates accounted for 1.7% of 
the total number of organism isolated from urine, blood, pus and sputum. 
Mindolli PB24 et al stated that Acinetobacter isolates accounted for 
4.25% of the total number of organism isolated. 
Kalidas Rit6 et al stated that Acinetobacter isolates accounted for 
4.5% of the total number of organism isolated. 
Lt Col kk Lahiri et al95 stated that Acinetobacter isolates accounted 
for 12.9% of the total number of organism isolated. 
Comparing to the above said studies, the isolation of Acinetobacter 
was less in the present study. 
Specimen wise prevalence:  
In th present study 32.5% of Acinetobacter were isolated from 
urine, followed by blood (27.5%), pus (26%) and sputum (14%) 
According to Mindolli et al24 isolation rate was higher in pus, 
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followed by urine (28%) sputum (25%) and blood (14%). 
According to Kalidas Rit et al6 isolation was higher in pus (48), 
followed by urine (40), sputum (35) , blood (22). 
 The two studies are in contrast to the present study as isolation 
rate was higher in pus. 
According to Lt Col KK Lahiri et al95 isolation was higher in urine 
(51.9%), blood (9.87%), sputum (12.5%) and pus (11.18%). This study 
supports the present study as isolation rate was higher in urine. But the 
isolation of blood in the present study was 27.5% which was high 
compared to the above study. 
       TABLE : 16 
SPECIMEN WISE PREVALENCE IN VARIOUS COUNTRIES 
                
SPECIMEN 
 
USA FRANCE BELGIUM GERMANY PRESENT 
STUDY 
URINE 27% 21% 27% 8.2% 32.5% 
SPUTUM 28.9% 27% 24.8% 48.8% 14% 
PUS 21.5% 27.5% 22.3% 16.4% 26% 
BLOOD 9.3% 7.5% 7.6% 26.6% 27.5% 
CATHETER 
TIPS 
0 15.5% 0 0 0 
OTHERS 13.3% 2% 18.3% 0 0 
138 
 
  The isolation rate of blood in the present study was more or less 
similar to the isolation rate in Germany.  
 
Age wise prevalence 
Kalidas Rit et al6 stated that Acinetobacter infection was more 
common in patients of age more than 40 years. 
Preeti B.Mindoli et al24 stated that Acinetobacter infection was 
more common in patients of age more than 45 years. 
Vijayan sivaranjani et al96 stated that Acinetobacter infection was 
more common in age group of 20-40years. 
Hilmar Wisplinghoff et al41 stated that no significant difference 
with regard to distribution of age was observed in Acinetobacter 
infection.  
In the present study among the 80 isolates of Acinetobacter, age 
group of more than 45 was more commonly affected, followed by 
paediatric age group (0-12) years. Since Acinetobacter infection was 
common among debilitated infection, in the present study old age were 
more commonly affected, followed by paediatrics. 
 The first two studies supports the present study. The third and 





Sex wise screening: 
In the present study among the 80 isolates of Acinetobacter, males 
(57.5%) were more commonly affected than females (42.5%). The male : 
female ratio was 1.4 : 1. 
According to Kalidas Rit et al6 the male : female ratio was 1.5 : 1. 
According to Mindolli PB et al24 the male : female ratio was 1.6 : 1. 
 All the above studies are more or less similar to the present study. 
In patient & out patient wise prevalence: 
In the present study isolation of Acinetobacter from In- patient was 
90% and out patient was 10%.  
According to Lt Col KK Lahiri95 the isolation of Acinetobacter 
from out patient was 17.1%. This study was more or less similar to the 
present study. Community acquired Acinetobacter was less compared to 
the hospital acquired Acinetobacter. Most of the community acquired 
Acinetobacter species was Acinetobacter lwoffii. 
 
Department wise prevalence: 
In the present study the highest rate of isolation was from ICU 
(32.5%). I included SNN, PICU, SICU, IMCU under ICU. All the isolates 
from paediatrics were from SNN, PICU. The isolation rate from surgical 




According to Mindolli PB et al24, most of the isolates were from 
surgical wards (30.5%) followed by ICU (27%), paediatric ward (19%), 
medicine ward (16.5%). 
According to Lt Col KK Lahiri et al95, most of the isolates were 
from Spinal cord injury centre (28.9%), followed by surgery (16.4%), 
family ward (11.1%), ICU (7.2%), Burns unit (7.2%), Medicine ward 
(4.6%) Ortho (3.9%). 
In the present study isolates from ICU (32.5%) was higher than the 
above said studies. 
 
Diagnosis wise prevalence: 
In the present study among the 80 isolates of Acinetobacter 31.5% 
affected by urinary tract infection, 26% affected by septicemia, 25% 
affected by wound infection and cellulitis and 17.5% affected by 
pneumonia. 
According to Alex studemeister97 40% affected by wound infection, 
30% affected by urinary tract infection, 20% affected by pneumonia and 
10% by septicemia. 
In the present study patients were more commonly affected by UTI, 





Different species of Acinetobacter isolated from clinical samples: 
In the present study 77.5% of the isolates were Acinetobacter 
baumannii, and 22.5% were Acinetobacter lwoffii. 
According to Mindolli PB et al24, 78% of the total Acinetobacter 
isolate were Acinetobacter baumannii, 12.5% Acinetobacter lwoffii, 6% 
Acinetobacter hemolyticus and 3% Acinetobacter junii. 
According to Kalidas Rit et al6 74.02% of isolates were 
Acinetobacter baumannii, 14.2% Acinetobacter lwoffii, 7.79% 
Acinetobacter hemolyticus, 3.3% Acinetobacter junni. 
According to K.Prashant et al25 71% of isolates were Acinetobacter 
baumannii, 20.3% Acinetobacter lwoffi, 3.38%, Acinetobater hemolyticus, 
1.6% Acinetobacter johnsonii, 1.6% Acinetobacter junii.  
All the above said studies are in correlation with the present study 
except the number of species, only two species were isolated.   
 
Imipenem resistance pattern of Acinetobacter: 
One of the striking features of Acinetobacter is its ability to develop 
antibiotic resistance extremely rapid in response to challenge with new 
antibiotic. In the present study Imipenem resistance was seen among 8% 
of the total isolates. Although Acinetobacter baumannii strains have 
intrinsic resistance to carbapenems, resistance to carbapenem is seen only, 
when there is upstream of insertion element ISAba1. Hence only 8% of 
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the isolates were resistant to Imipenem. All Acinetobacter lwoffii strains 
were sensitive to Imipenem. Isolates resistant to Imipenem were sensitive 
to polymyxin and colistin. 
Kalidas Rit et al6 stated that Imipenem resistance was seen among 
5.2% of the total isolates. 
Vijayan Sivaranjani et al96 stated that Imipenem resistance was 
seen among 26.2% of the total isolates. 
Comparing to Kalidas Rit et al6, in the present study imipenem 
resistance was higher. But comparing to Vijayan Sivaranjani et al, the 
resistance rate was lower. 
 
Resistance pattern of Acinetobacter to various antibiotics:  
In the present study 81% resistant to Ampicillin, 36% resistant to 
Gentamicin, 29% resistant to Amikacin, 86% resistant to Cephalexin, 
44% resistant to Ceftriaxone, 49% resistant to Ciprofloxacin, 55% 
resistant to Cotrimoxazole, 66% resistant to Chloramphenicol. 
Acording to Vijayan Sivaranjani et al97, 86.8% resistant to 
Ampicillin, 51.6% resistant to Amikacin, 60.6% resistant to Gentamicin, 
59.8% resistant to Cotrimoxazole, 69.6% resistant to Ciprofloxacin. 
According to Kalidas Rit et al6, 14.29% resistant to Amikacin, 
70.13% resistant to Gentamicin, 42.21% resistant to Ofloxacin, 92.20% 
resistant to Chloramphenicol. 
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According to Mindolli PB et al24, 37.5% resistant to Amikacin, 
47.5% resistant to Gentamicin, 73.5% resistant to Ofloxacin, 88.5% 
resistant to Chloramphenicol. 
The difference in the sensitivity pattern was due to environmental 
factors and different pattern of antimicrobial usage. In the present study, 
isolates were more resistant to Ampicillin, Cephalexin and more sensitive 
to Amikacin and Imipenem.Vijayan Rit et al study is similar to the 
present study. Mindolli et al and Kalidas Rit et al studies stated that 
isolates were more resistant to Chloramphenicol, this is in contrast to the 
present study. But isolates were more sensitive to Amikacin, this is 
similar to the present study. 
Detection of blaOXA-51 gene: 
 Conventional PCR was done for 14 Acinetobacter isolates (8 
Imipenem sensitive Acinetobacter baumannii, 4 Imipenem resistant 
Acinetobacter baumannii and two Acinetobacter lwoffii). Since blaOXA-51 
gene was intrinsic gene present in Acinetobacter baumannii, all 
Acinetobacter baumannii of both Imipenem sensitive and resistant were 




According to Jane F turton et al98, blaOXA-51 was detected in all 
Acinetobacter baumannii strains and it was not detected in other species 
of Acinetobacter. 
This study supports the present study. 
Limitation of present study: 
 Restricted use of molecular method due to lack of affordability. 
 Automated systems were not used due to lack of availability. 
 Follow up of cases not done. 
Strength of present study: 
 Selective media, Leeds Acinetobacter media was used . 
 Speciation was done by both biochemical test and molecular 
method. 
 BlaOXA gene, an intrinsic gene of Acinetobacter baumannii was 
detected by the conventional PCR for confirmation of species. 
Suggestions: 
1. Avoiding indriscriminate use of antibiotics by ensuring that the 
indication, the dose and duration of treatment are appropriate. 
2. Constantly monitoring the resistance patterns in a hospital or 
community and change recommended antibiotics used for 
empirical treatment and limiting the usage of newest group of 




3. Maintenance of infection control in hospitals, such as isolation 
and treatment of carriers, hand hygiene practices for ward staff 
to prevent spread of resistant bacteria. 
4. Conducting periodic educational programmes on antimicrobial 
use for the practitioners in order to limit the use of newer drugs 
and to minimize the antibiotic resistance. 
 
 


































Identification, speciation, antibiogram and molecular characterization of 
Acinetobacter isolated from various clinical samples received in 24 hours 
Microbiology diagnostic laboratory, Thanjavur Medical College and 
Hospital were aimed in finding out the prevalence of Acinetobacter and 
its resistant pattern during the study period of June 2013 to May 2014. 
Eighty Acinetobacter were isolated and they were subjected to speciation, 
antibiogram and molecular characterization. They were analysed on the 
basis of specimen wise, age wise, sex wise screening etc. 
 The prevalence of Acinetobacter was 1.7%. Isolation was more in 
urine samples. Males and age group of 45 years and above were 
predominantly affected. 
 90% of Acinetobacter were isolated from In - patients and 
predominantly from ICU (32.5%). 
 Acinetobacter baumannii (77.5%) and Acinetobacter lwoffii (22.5%) 
were the two species isolated. 
 8% of the total isolates were resistant to Imipenem. The isolates 
resistant to imipenem were sensitive to Polymyxin and Colistin. 
 Molecular characterization by conventional PCR was done for 14 
Acinetobacter isolates. BlaOXA -51 was detected in all the 12 
Acinetobacter baumannii strains of both Imipenem sensitive and 





















Identification, speciation, antibiogram, and molecular characterization of 
Acinetobacter isolated from various clinical samples received in 24 hours 
Microbiology diagnostic laboratory, Thanjavur Medical College and 
Hospital reveals that  
 The prevalence of Acinetobacter was 1.7%. During routine 
microbiological work nonfermentative Gram negative bacilli other 
than Pseudomonas aeruginosa are not taken seriously and are 
considered as contaminants. But the rate of isolation of 
Acinetobacter indicates its role in nosocomial pathogen. 
 The predominant species isolated was Acinetobacter baumannii 
more commonly from In patients, that too from ICU. Hence 
Acinetobacter baumannii more commonly causes hospital acquired 
serious infections.   
 Increasing resistant pattern was seen for the commonly used drugs 
like Ampicillin, Cephalosporins, Ciprofloxacin, Cotrimoxazole, 
Chloramphenicol. 8% of the isolates were resistant to Imipenem. 
All the 8% were Acinetobacter baumannii and none of the 
Acinetobacter lwoffii strains were resistant to Imipenem.  
 Molecular Characterization by conventional PCR revealed that 




Acinetobacter baumannii has beta lactamase oxacillinase 51 gene   
(blaOXA -51 gene) which is an intrinsic gene. But resistance to imipenem is 
expressed only when insertional element ISAba1 is overexpressed. 
Acinetobacter baumannii has a remarkable ability to upregulate or 
acquire resistant determinants. Acinetobacter baumannii is an emerging 
pathogen threatening the current antibiotic era.  
 Drug resistance pattern varies from place to place which may be 
related to the nature of the pathogen and preferred antimicrobial agents. 
Hence institutional antibiotic policy should be monitored to achieve 
superior therapeutic outcome and bring about a reduction in healthcare 
costs.The easiest way to prevent the infection is preventive measures like 

































                     PROFORMA 
Name:                                  Ward :                                          
Age:                                    Lab No:                                                            
Sex:                                    OP / IP No:                                           
Address:                                 Date of Sample Collection:                                         
Occupation:                              Specimen:                               
Income :                                 Test:                                                                                                                             





Past  History : 
1.Tuberculosis 





Personal  History:  Smoker-                           Alcoholic- 





Specimen: Urine, Pus, Blood, Sputum 
I Culture :  1. MacConkey agar 
   2. Blood agar 
   3. Nutrient agar 
II Gram Staining 
III Hanging drop 
IV Biochemical Reaction:   1. Catalase 
       2. Oxidase 
       3. Indole 
       4. Methyl red  
       5. Voges proskauer 
       6. Citrate Utilisation test 
       7. Urease 
       8.TSI 
       9.Nitrate reduction test 
V Culture on Selective media : Leed’s Acinetobacter medium 
VI Speciation :   1. Hemolysis 
    2. Growth at 37◦C and 42◦C 
    3. OF test 
    4. Arginine decarboxylase test 
    5.1% lactose and 10% lactose 
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    6. Susceptibility to Chloramphenical 











II line drugs : 
1. Doxycycline 
2. Piperacillin 










 PREPARATION OF MEDIA AND REAGENTS 
Gram stain: 
Methyl violet: 
   Methyl violet – 1.5 gm  
Distilled water – 100 ml 
Grams iodine 
Potassium iodide – 2 gm 
Iodine  - 2 gm 
Water – 100 ml 
Dilute carbol fuchscin: 
Strong carbol fuchscin: 
Basic fuchscin – 0.5 gm  
Phenol crystal – 2.5 gm  
Alcohol – 10 ml 
 Water - 90 ml 
Take 1 ml of strong carbol fuchscin and add 19 ml of distill water. 
MacConkey agar plate : 
5.5 gm dehydrated MacConkey agar is taken and 100 ml distilled 
water is added. Then it is heated to dissolve completely. pH adjusted to 




Nutrient agar plate: 
2.8 gm of dehydrated nutrient agar powder is taken and 100 ml of 
distill water is added. It was boiled to dissolve it completely. pH is 
adjusted to 7.4. Autocalved at 121oC for 15 min and plated. 
Blood agar plate : 
8 ml of human blood is added to the prepared nutrient agar. Mix 
thoroughly .then autoclaved at 121oC for 15 min and plated 
Methyl Red Test: 
MR-VP broth :  
1.7 gm of glucose phosphate broth is taken and 100 ml distilled water 
is added and it heated to dissolve completely. pH adjusted to 6.9. 
Then autoclaved at 121oC for 15 min.Then dispensed in separate 
tubes. 
MR reagent: 
 Methyl red - 0.1 gm 
95 % Ethyl alcohol – 300 ml 
VP reagent 1: 
α- naphthol – 5 gm 
Absolute ethyl alcohol – 100 ml 
VP reagent 2: 
Potassium hydroxide – 40 gm 




Peptone water:      
      Peptone  - 5gm 
Sodium chloride – 2.5 gm 
Water – 500 ml 
Autoclave at 121oC for 15 minutes 
 
Citrate Utilization test 
2.428 gm of dehydrated citrate powder is taken in a conical flask and 100 
ml of distilled water is added. It was boiled till it dissolved completely. 
pH adjusted to 6.8. Then autoclaved at 121oC for 15 min. 
Urease Test: 
2.401 gm of dehydrated urea agar base is taken and 95 ml of distilled 
water is added. It was boiled to dissolve it completely. pH adjusted to 6.8. 
Then autoclaved at 121oC for 15 min and then cooled to 50oC. 5 ml of 
40% of urease solution is added. 
Triple Sugar Iron agar: 
6.452 gm of dehydrated medium is taken and mixed with 100 ml of distill 
water. Then it is heated to dissolve. pH is adjusted to 7.4.Then autoclaved 
at 121o C for 15 min. Then it is dispensed in test tubes in such a way to 





0.9 gm of dehydrated medium is taken and mixed with 100 ml of distilled 
water. Heat to dissolve completely. pH is adjusted to 7. Then autoclave at 
121o C for 15 min. Then it is dispensed in test tubes. 
Nitrate reagent: 
α- Naphthylamine – 0.5 gm 
        30% Acetic acid – 100 ml 
Leeds Acinetobacter media plate : 
5.32 gm of   Leeds Acinetobacter media was taken and 100 ml of 
distilled water is added and kept in water bath at 100oC for 45 min. pH 
adjusted to 7.Then cooled to 50oC and plated. 
Mueller-Hinton agar plate : 
3.8 gm of dehydrated media is taken and 100 ml of distilled water is 
added. Then it is heated  to dissolve completely. pH is adjusted to 
7.3.Them autoclaved at 121oC for 15 min. Then plated. 
 
1% Lactose : 
Take 1 gram of lactose and add 100 ml of distilled water. Add the 
indicator bromothymol blue to 100 ml of peptone water and adjust the pH 
to 7.5. Distribute in tubes (add 250 µl of sugar solution to each 5ml of 





10% Lactose : 
Take 10 gram of lactose and add 100 ml of distilled water. Add  the 
indicator bromothymol blue to 100 ml of peptone  water and adjust the 
pH to 7.5. Distribute in tubes (add 250 µl of sugar solution to each 5ml of 
peptone water ). Keep it water bath for 15 min. 
OF Test: 
1.935 gm of dehydrated Hugh-Leifson’s OF medium  is taken and 
100 ml of distilled water is added and  boiled it to dissolve completely . 
pH adjusted to 6.8 and then dispenced in separate tubes. Autoclaved at 
121oC for 15 min. 
Arginine: 
1.052 gm of dehydrated decarboxylase base is taken and 100 ml of 
distilled water is added. 10 gm of arginine is added and boiled to dissolve 
it completely. pH adjusted to 6. Dispensed in 5 ml amounts in separate 
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